Page last updated: 2024-08-03 16:44:33

bms 708163

Description

BMS 708163: structure in first source [MeSH]

Avagacestat : no description available [CHeBI]

Cross-References

ID Source	ID
PubMed CID	46883536
CHEMBL ID	1090771
SCHEMBL ID	310019
CHEBI ID	177493
MeSH ID	M0552493

Synonyms (65)

Synonym
HY-50845
CHEBI:177493
avagacestat
1146699-66-2
(2r)-2-[(4-chlorophenyl)sulonyl-[[2-luoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-triluoropentanamide
AKOS005146523
CHEMBL1090771
bms-708163-01
bms 708163
bms-70816301
bms-708163 ,
avagacestat (usan)
D09869
(2r)-2-(n-((4-chlorophenyl)sulfonyl)-n-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide
tq44wwy45q ,
unii-tq44wwy45q
avagacestat [usan:inn]
BCP9000429
bms708163
AKOS016016280
(2r)-5,5,5-trifluoro-2-(n-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl}4-chlorobenzenesulfonamido)pentanamide
BCPP000327
BCP0726000124
NCGC00346504-01
CS-0180
S1262
(2r)-2-[n-[(4-chlorophenyl)sulfonyl]-n-[2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl]amino]-5,5,5-trifluoropentanamide
gtpl6489
SCHEMBL310019
smr004676648
MLS006011074
bms-708163 (avagacestat)
(2r)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide
avagacestat [usan]
avagacestat [inn]
pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2r)-
avagacestat [who-dd]
DTXSID40150811
mfcd13195458
(2r)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-pentanamide
avagacestat, >=98% (hplc)
(2r)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide
AS-75078
MRF-0000009
(r)-2-(4-chloro-n-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)-phenylsulfonamido)-5,5,5-trifluoropentanamide
SW218162-2
avagacestat (bms-708163)
DB11893
BCP01770
(r)-2-((4-chloro-n-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenyl)sulfonamido)-5,5,5-trifluoropentanamide
(2r)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-pentanamide
Q27074630
avagacestat; bms-708163
EX-A2871
pentanamide, 2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-, (2r)-
HMS3884O07
CCG-269860
nsc761217
nsc-761217
(2r)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoranyl-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-tris(fluoranyl)pentanamide
en9 ,
C71464
bdbm50458169
bms-708163;(r)-2-(4-chloro-n-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5,5,5-trifluoropentanamide
A894166

Drug Classes (2)

Class	Description
oxadiazole
ring assembly	Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.

Protein Targets (7)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	14.4732	AID1259252; AID1259253; AID1259255; AID1259256

Inhibition Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Presenilin-1	Homo sapiens (human)	IC50	0.0006	AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Presenilin-2	Homo sapiens (human)	IC50	0.0006	AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Gamma-secretase subunit APH-1B	Homo sapiens (human)	IC50	0.0006	AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Nicastrin	Homo sapiens (human)	IC50	0.0006	AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Gamma-secretase subunit APH-1A	Homo sapiens (human)	IC50	0.0006	AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Gamma-secretase subunit PEN-2	Homo sapiens (human)	IC50	0.0006	AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856

Other Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Presenilin-1	Homo sapiens (human)	ED50	0.0012	AID754313
Presenilin-2	Homo sapiens (human)	ED50	0.0012	AID754313
Gamma-secretase subunit APH-1B	Homo sapiens (human)	ED50	0.0012	AID754313
Nicastrin	Homo sapiens (human)	ED50	0.0012	AID754313
Gamma-secretase subunit APH-1A	Homo sapiens (human)	ED50	0.0012	AID754313
Gamma-secretase subunit PEN-2	Homo sapiens (human)	ED50	0.0012	AID754313

Bioassays (101)

Assay ID	Title	Year	Journal	Article
AID755848	Oxidative metabolism in rat liver microsomes assessed as compound remaining	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671906	Thermodynamic solubility of the compound at pH 6.5	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755849	Oxidative metabolism in dog liver microsomes assessed as compound remaining	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID755843	Glucuronidation metabolism in human liver microsomes assessed as compound remaining	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671926	Cmax in 129/sve mouse plasma at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755854	Selctivity ratio of IC50 for partially purified human gamma-secretase-mediated cleavage of notch fusion protein to IC50 for partially purified human gamma-secretase-mediated cleavage of MBP-APPc125Sw fusion protein	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID672066	Antialzheimer activity in 129/sve mouse assessed as reduction in amyloid beta40 level in CSF at 30 mg/kg, po administered as single dose measured at 2 hrs by ELISA relative to vehicle treated control	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755852	Inhibition of gamma-secretase in CHO cells assessed expressing NotchdeltaE assessed as inhibition of notch cleavage after overnight incubation by luciferase reporter gene assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID1650829	Drug concentration in Beagle dog plasma at 3 mg/kg, po measured at 24 hrs	2020	Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3 ISSN: 1464-3405	An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID1383005	Selectivity ratio of IC50 for inhibition of gamma-secretase (unknown origin) assessed as notch cleavage to IC50 for inhibition of gamma-secretase (unknown origin) assessed as APP cleavage	2018	European journal of medicinal chemistry, Mar-25, Volume: 148ISSN: 1768-3254	Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead.
AID1650826	Cmax in Beagle dog at 3 mg/kg, po	2020	Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3 ISSN: 1464-3405	An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID1383009	Inhibition of gamma-secretase in human H4-8Sw cells assessed as reduction in amyloid beta (1 to 42) formation	2018	European journal of medicinal chemistry, Mar-25, Volume: 148ISSN: 1768-3254	Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead.
AID755812	Reduction in amyloid beta (x to 40) in FVB mouse cortex at 3 mg/kg, po administered as single dose measured at 3 hrs	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671935	Tmax in 129/sve mouse cerebrospinal fluid at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671927	Tmax in 129/sve mouse plasma at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755847	Oxidative metabolism in human liver microsomes assessed as compound remaining	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671929	Cmax in 129/sve mouse brain at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID672065	Antialzheimer activity in 129/sve mouse assessed as reduction in amyloid beta42 level in brain at 30 mg/kg, po administered as single dose measured at 4 hrs by ELISA relative to vehicle treated control	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755846	Glucuronidation metabolism in mouse liver microsomes assessed as compound remaining	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID630268	Selectivity for gamma secretase over notch cleavage	2011	Journal of medicinal chemistry, Nov-24, Volume: 54, Issue:22 ISSN: 1520-4804	Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors.
AID754317	Inhibition of gamma-secretase in human IMR32 cell membrane using Notch as substrate after 2 hrs by ELISA	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4 ISSN: 1464-3405	Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID671928	AUC (0 to 18 hrs) in 129/sve mouse plasma at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID672071	Fraction unbound in 129/sve mouse plasma at 30 mg/kg, po administered as single dose	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671934	Cmax in 129/sve mouse cerebrospinal fluid at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755851	Selctivity ratio of ED50 for gamma-secretase in CHO cells assessed expressing NotchdeltaE assessed as inhibition of notch cleavage to ED50 for gamma-secretase in CHO cells assessed expressing APPSw assessed as inhibition of amyloid beta(1 to x) secretion	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID755844	Glucuronidation metabolism in rat liver microsomes assessed as compound remaining	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671903	Apparent total intrinsic clearance in human liver microsomes assessed per million cells	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755813	Reduction in amyloid beta (x to 40) in FVB mouse cortex at 1 mg/kg, po administered as single dose measured at 3 hrs	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID755810	Reduction in amyloid beta (x to 40) in FVB mouse cortex at 10 mg/kg, po administered as single dose measured at 3 hrs	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671913	Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671902	Apparent total intrinsic clearance in human hepatocytes assessed per million cells	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671931	AUC (0 to 18 hrs) in 129/sve mouse brain at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671908	Efflux ratio of apparent permeability from basal to apical side to apical to basal side of MDCK cells expressing human P-gp	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671905	Kinetic solubility of the solubility of the compound at pH 6.5	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475567	Inhibition of gamma secretase-mediated total amyloid beta production in healthy human CSF at 200 mg/kg administered as single dose	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20 ISSN: 1520-4804	Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID697324	Inhibition of gamma-secretase	2012	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 ISSN: 1464-3405	2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as γ-secretase inhibitors.
AID671901	Selectivity for human gamma-seretase over notch signalling protein	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671910	Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755856	Inhibition of partially purified human gamma-secretase-mediated cleavage of MBP-APPc125Sw fusion protein measured after overnight incubation by ELISA	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID1650827	AUC (0 to 24 hrs) in Beagle dog at 3 mg/kg, po	2020	Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3 ISSN: 1464-3405	An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID672067	Antialzheimer activity in 129/sve mouse assessed as reduction in amyloid beta40 level in plasma at 30 mg/kg, po administered as single dose measured at 0.5 hrs by ELISA relative to vehicle treated control	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755855	Inhibition of partially purified human gamma-secretase-mediated cleavage of notch fusion protein measured after overnight incubation by ELISA	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID754313	Inhibition of gamma-secretase in HEK293 cells after overnight incubation by Western blotting analysis	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4 ISSN: 1464-3405	Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID671930	Tmax in 129/sve mouse brain at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671912	Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID672064	Antialzheimer activity in 129/sve mouse assessed as reduction in amyloid beta40 level in brain at 30 mg/kg, po administered as single dose measured at 4 hrs by ELISA relative to vehicle treated control	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475565	Half life in healthy human at 200 mg/kg administered as single dose	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20 ISSN: 1520-4804	Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID755811	Reduction in amyloid beta (x to 40) in FVB mouse cortex at 30 mg/kg, po administered as single dose measured at 3 hrs	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID755853	Inhibition of gamma-secretase in CHO cells assessed expressing APPSw assessed as inhibition of amyloid beta(1 to x) secretion after overnight incubation by ELISA	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671936	AUC (0 to 18 hrs) in 129/sve mouse cerebrospinal fluid at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID754315	Ratio of IC50 for gamma-secretase in human IMR32 cells using Notch as substrate to IC50 for gamma-secretase in human IMR-32 cells using APP as substrate	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4 ISSN: 1464-3405	Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID755850	Oxidative metabolism in mouse liver microsomes assessed as compound remaining	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID1650828	Tmax in Beagle dog at 3 mg/kg, po	2020	Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3 ISSN: 1464-3405	An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID672072	Fraction unbound in 129/sve mouse brain at 30 mg/kg, po administered as single dose	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475563	Inhibition of human gamma secretase-mediated amyloid beta (1 to 40) production expressed in human H4 cells	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20 ISSN: 1520-4804	Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID671904	Apparent permeability from apical to basal side of dog RRCK cells	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID1650823	Aqueous solubility of compound at pH 6.5	2020	Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3 ISSN: 1464-3405	An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID671907	Thermodynamic solubility of the compound at pH 7.4	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475566	Inhibition of gamma secretase-mediated total amyloid beta production in healthy human plasma at 200 mg/kg administered as single dose	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20 ISSN: 1520-4804	Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID671911	Inhibition of CYP2C19 in human liver microsomes using (S)-mephenytoin as substrate	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475564	Selectivity for human gamma secretase-mediated amyloid beta (1 to 40) production over human gamma secretase-mediated notch processing	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20 ISSN: 1520-4804	Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID671909	Inhibition of CYP1A2 in human liver microsomes using tacrine as substrate	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671933	Ratio of unbound fraction in brain to unbound fraction in plasma in 129/sve mouse at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671900	Inhibition of gamma secretase-mediated amyloid beta42 production in human H4 cells expressing human APP swedish mutant	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671932	Ratio of drug level in brain to plasma in 129/sve mouse at 30 mg/kg, po administered as single dose by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 ISSN: 1520-4804	Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID754314	Inhibition of gamma-secretase in CHO cells after overnight incubation by luciferase reporter gene assay	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4 ISSN: 1464-3405	Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID754316	Inhibition of gamma-secretase in human IMR32 cell membrane using APP as substrate after 2 hrs by ELISA	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4 ISSN: 1464-3405	Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID754312	Ratio of IC50 for gamma-secretase in CHO cells using Notch as substrate to ED50 for gamma-secretase in HEK293 cells using APP as substrate	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4 ISSN: 1464-3405	Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID755845	Glucuronidation metabolism in dog liver microsomes assessed as compound remaining	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 ISSN: 1520-4804	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3 ISSN: 1754-8411	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3 ISSN: 1754-8411	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.

Research

Studies (46)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (2.17)	29.6817
2010's	34 (73.91)	24.3611
2020's	11 (23.91)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (10.87%)	5.53%
Reviews	4 (8.70%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (2.17%)	0.25%
Other	36 (78.26%)	84.16%

Substance	Classes	Roles	Relationship Strength
molsidomine	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent	low
oxolamine	oxadiazole; ring assembly		low
imolamine	oxadiazole; ring assembly		low
5-(2-ethoxyphenyl)-3-(2-methoxy-6-methyl-3-pyridinyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
N-(4-chlorophenyl)-4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinecarboxamide	oxadiazole; ring assembly		low
N-tert-butyl-2-[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]benzamide	oxadiazole; ring assembly		low
3-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-N-(3-pyridinyl)propanamide	oxadiazole; ring assembly		low
3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-methylpropanamide	oxadiazole; ring assembly		low
3-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-N-(3-methylphenyl)propanamide	oxadiazole; ring assembly		low
3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-ethylpropanamide	oxadiazole; ring assembly		low
[2-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]-(1-pyrrolidinyl)methanone	oxadiazole; ring assembly		low
5-(3,5-dimethoxyphenyl)-3-(2-methoxyphenyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
5-(3-chloro-4-methylphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole	oxadiazole; ring assembly		low
5-(3,5-dimethoxyphenyl)-3-phenyl-1,2,4-oxadiazole	oxadiazole; ring assembly		low
3-(4-methoxyphenyl)-5-(4-methylphenyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
3-(4-methoxyphenyl)-5-(2-phenylethyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
5-[(4-methylphenoxy)methyl]-3-phenyl-1,2,4-oxadiazole	oxadiazole; ring assembly		low
3-(2-methoxy-6-methyl-3-pyridinyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
5-(3,4-diethoxyphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole	oxadiazole; ring assembly		low
5-(5-bromo-2-chlorophenyl)-3-pyridin-4-yl-1,2,4-oxadiazole	oxadiazole; ring assembly		low
N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-2-thiophenecarboxamide	oxadiazole; ring assembly		low
N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-2-(2,3,5-trimethylphenoxy)acetamide	oxadiazole; ring assembly		low
3-phenyl-5-[[[4-phenyl-5-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]thio]methyl]-1,2,4-oxadiazole	oxadiazole; ring assembly		low
2,5-dichloro-N-methyl-N-[[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]benzenesulfonamide	oxadiazole; ring assembly		low
3-(4-bromophenyl)-5-(3,5-dimethoxyphenyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
4-morpholinyl-[4-[3-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methanone	oxadiazole; ring assembly		low
5-(6-chloro-3-pyridinyl)-3-(3-methoxyphenyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
3-(2-chlorophenyl)-N-cyclohexyl-5-methyl-N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-4-isoxazolecarboxamide	oxadiazole; ring assembly		low
5-(2,3-dihydrobenzofuran-5-yl)-3-(4-fluorophenyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
5-[[(1-cyclohexyl-5-tetrazolyl)thio]methyl]-3-phenyl-1,2,4-oxadiazole	oxadiazole; ring assembly		low
1-[3-[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-1-butanone	oxadiazole; ring assembly		low
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(2-pyridinylthio)methyl]-4-triazolecarboxylic acid propan-2-yl ester	aryl sulfide; azole; isopropyl ester; oxadiazole; pyridines		low
2-(2-methoxyphenyl)-N-[4-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide	oxadiazole; ring assembly		low
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]propanamide	oxadiazole; ring assembly		low
2-(4-methoxyphenyl)-N-[4-[5-(3,4,5-trimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide	oxadiazole; ring assembly		low
N-(5-chloro-2,4-dimethoxyphenyl)-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]propanamide	oxadiazole; ring assembly		low
N-ethyl-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-N-(phenylmethyl)propanamide	oxadiazole; ring assembly		low
3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)propanamide	oxadiazole; ring assembly		low
N-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]propanamide	oxadiazole; ring assembly		low
N-ethyl-N-(2-ethylphenyl)-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]propanamide	oxadiazole; ring assembly		low
N-[4-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]-2-(4-methoxyphenyl)acetamide	oxadiazole; ring assembly		low
3-(5-bromo-2-furanyl)-5-(4-methoxyphenyl)-1,2,4-oxadiazole	oxadiazole; ring assembly		low
sew2871	oxadiazole; ring assembly		low
3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole-5-carboxylic acid ethyl ester	oxadiazole; ring assembly		low
5-chloro-2-methoxy-N-[[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]-N-propan-2-ylbenzamide	oxadiazole; ring assembly		low
molsidomine	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent	low
N,2-dimethyl-N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-3-furancarboxamide	oxadiazole; ring assembly		low
ptc 124	oxadiazole; ring assembly		low
1-ethyl-4-[[methyl-[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]amino]methyl]-2-pyrrolidinone	oxadiazole; ring assembly		low
cym-5442	oxadiazole; ring assembly		low
4-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid	oxadiazole; ring assembly		low
AZD1979	aromatic ether; azaspiro compound; carboxamide; N-acylazetidine; oxadiazole; oxaspiro compound; oxetanes	melanin-concentrating hormone receptor antagonist	low
opicapone	oxadiazole; ring assembly		low
my 5445	pyridazines; ring assembly		low
famprofazone	pyrazoles; ring assembly		low
nafoxidine	benzenes; naphthalenes; ring assembly		low
nifenazone	pyrazoles; ring assembly		low
1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
ramifenazone	pyrazoles; ring assembly		low
4-[6-amino-3-(4-methoxyphenyl)-1-pyridazin-1-iumyl]butanoic acid	pyridazines; ring assembly		low
difenzoquat	pyrazoles; ring assembly		low
irinotecan	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug	low
n-demethylantipyrine	pyrazoles; ring assembly		low
4-Formyl-antipyrine	pyrazoles; ring assembly		low
5-amino-1-phenyl-1H-pyrazole-4-carbonitrile	pyrazoles; ring assembly		low
benzpiperylone	pyrazoles; ring assembly		low
4-hydroxyantipyrine	pyrazoles; ring assembly		low
galgravin	aryltetrahydrofuran; dimethoxybenzene; lignan; ring assembly	bone density conservation agent; neuroprotective agent; plant metabolite; platelet aggregation inhibitor	low
cl 218872	pyridazines; ring assembly		low
3-phenyl-1H-pyrazole-5-carboxylic acid	pyrazoles; ring assembly		low
3-(2-hydroxy-4-(1,1-dimethylheptylphenyl)cyclohexan-1-ol)	alkylbenzene; ring assembly		low
kolaviron	4'-methoxyflavanones; biflavonoid; dihydroflavonols; ring assembly; secondary alpha-hydroxy ketone	hepatoprotective agent; plant metabolite	low
cgs 20625	pyrazoles; ring assembly		low
chondroitin sulfate E (GalNAc4,6diS-GlcA), precursor 3	pyrazoles; ring assembly		low
N-tert-butyl-6-ethyl-1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
diospyrin	hydroxy-1,4-naphthoquinone; ring assembly		low
4-methyl-7-phenyl-3-pyrazolo[5,1-c][1,2,4]triazinecarboxylic acid ethyl ester	pyrazoles; ring assembly		low
4-amino-2,6-dimethyl-5-[3-(4-methylphenyl)-1H-pyrazol-5-yl]-3-pyridazinone	pyrazoles; ring assembly		low
1-phenyl-4-pyrazolol	pyrazoles; ring assembly		low
4,5-diphenyl-1,2,3-triazole	benzenes; ring assembly; triazoles		low
7-amino-2-methyl-3-phenyl-6-pyrazolo[1,5-a]pyrimidinecarbonitrile	pyrazoles; ring assembly		low
4-(4-hydroxy-3,5-dimethylphenyl)-2-methylphthalazin-1(2H)-one	pyridazines; ring assembly		low
N,N-dimethyl-6-phenyl-3-pyridazinamine	pyridazines; ring assembly		low
6-amino-4-(2,3-dimethoxyphenyl)-3-methyl-1-phenyl-4H-pyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; ring assembly		low
4-[2-(3-fluorophenyl)-5-methyl-7-pyrazolo[1,5-a]pyrimidinyl]morpholine	pyrazoles; ring assembly		low
2-[[6-(3,4-dimethoxyphenyl)-3-pyridazinyl]thio]-1-(1-pyrrolidinyl)ethanone	pyridazines; ring assembly		low
4-[2-(3-fluorophenyl)-5,6,7,8-tetrahydropyrazolo[5,1-b]quinazolin-9-yl]morpholine	pyrazoles; ring assembly		low
6-amino-4-(2,5-dimethoxyphenyl)-3-methyl-1-(4-methylphenyl)-4H-pyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; ring assembly		low
2-[[2-(4-methoxyphenyl)-5-methyl-7-pyrazolo[1,5-a]pyrimidinyl]amino]ethanol	pyrazoles; ring assembly		low
4-[3-(4-fluorophenyl)-2,5,6-trimethyl-7-pyrazolo[1,5-a]pyrimidinyl]morpholine	pyrazoles; ring assembly		low
2-[2-[[2-[[1-(4-methoxyphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]thio]-1-oxoethyl]amino]-4-thiazolyl]acetic acid ethyl ester	pyrazoles; ring assembly		low
LSM-34623	pyrazoles; ring assembly		low
2-[[6-(3,4-dimethoxyphenyl)-3-pyridazinyl]thio]-1-(4-morpholinyl)ethanone	pyridazines; ring assembly		low
2-[[1-(4-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]thio]acetic acid ethyl ester	pyrazoles; ring assembly		low
2-[(3-oxo-5-phenyl-1,2-dihydropyrazol-4-yl)-(3-thiophenyl)methyl]propanedinitrile	pyrazoles; ring assembly		low
N-[2-(1-cyclohexenyl)ethyl]-1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
5-[(3-ethoxycarbonyl-4-thiophen-2-yl-2-thiophenyl)amino]-5-oxopentanoic acid	ring assembly; thiophenes		low
N-(2-oxolanylmethyl)-1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
1-phenyl-N-(3-propan-2-yloxypropyl)-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
2-[2-[[1-(4-chlorophenyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]ethoxy]ethanol	pyrazoles; ring assembly		low
1-(4-chlorophenyl)-N-(1-methoxypropan-2-yl)-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
1-[1-(4-methoxyphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]-4-piperidinecarboxamide	pyrazoles; ring assembly		low
2-[2-[(1-phenyl-4-pyrazolo[3,4-d]pyrimidinyl)amino]ethoxy]ethanol	pyrazoles; ring assembly		low
LSM-17424	pyrazoles; ring assembly		low
LSM-19719	pyrazoles; ring assembly		low
2-[2-oxo-2-[4-(4-phenyl-1-phthalazinyl)-1-piperazinyl]ethyl]isoindole-1,3-dione	pyridazines; ring assembly		low
LSM-28231	pyrazoles; ring assembly		low
2,6-dimethyl-4-(1-phenyl-4-pyrazolyl)furo[2,3-d]pyrimidine	pyrazoles; ring assembly		low
3-phenyl-1H-cinnolin-4-one	pyridazines; ring assembly		low
Glyceryl lactopalmitate	pyrazoles; ring assembly		low
2-[(2,5-dimethyl-3-phenyl-7-pyrazolo[1,5-a]pyrimidinyl)thio]acetonitrile	pyrazoles; ring assembly		low
7-(3,5-dimethyl-1-pyrazolyl)-5-methyl-3-phenylpyrazolo[1,5-a]pyrimidine	pyrazoles; ring assembly		low
6-amino-1-(4-fluorophenyl)-3-methyl-4-thiophen-2-yl-5-pyrazolo[3,4-b]pyridinecarbonitrile	pyrazoles; ring assembly		low
4-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrazol-5-amine	pyrazoles; ring assembly		low
2-(4-bromophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine	pyrazoles; ring assembly		low
2-(4-bromophenyl)-4-methyl-1H-pyrazol-5-one	pyrazoles; ring assembly		low
1-(3-methylphenyl)-N-(2-pyridinylmethyl)-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
1,3-diphenyl-4-pyrazolecarbonitrile	pyrazoles; ring assembly		low
N-tert-butyl-1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
5-(4-cyclohexylphenyl)-1,2-dihydropyrazol-3-one	pyrazoles; ring assembly		low
2-[(dimethylamino)methyl]-4-methyl-6-(1-methylcyclohexyl)phenol	alkylbenzene; ring assembly		low
2-(3-oxo-2-phenyl-1H-pyrazol-5-yl)acetic acid methyl ester	pyrazoles; ring assembly		low
4-hydroxy-1-(4-methylphenyl)-3-pyrazolecarboxylic acid ethyl ester	pyrazoles; ring assembly		low
1-(4-fluorophenyl)-4-hydroxy-3-pyrazolecarboxylic acid ethyl ester	pyrazoles; ring assembly		low
4-(3,5-dimethyl-1-pyrazolyl)-6-methyl-1-phenylpyrazolo[3,4-d]pyrimidine	pyrazoles; ring assembly		low
5,7-dimethyl-2-phenylpyrazolo[1,5-a]pyrimidine	pyrazoles; ring assembly		low
5-(methoxymethyl)-2-phenyl-1H-pyrazolo[1,5-a]pyrimidin-7-one	pyrazoles; ring assembly		low
3-(4-chlorophenyl)-2,5-dimethyl-1H-pyrazolo[1,5-a]pyrimidin-7-one	pyrazoles; ring assembly		low
2-(5,7-dimethyl-3-phenyl-6-pyrazolo[1,5-a]pyrimidinyl)acetic acid ethyl ester	pyrazoles; ring assembly		low
5,7-dimethyl-2-(4-methylphenyl)pyrazolo[1,5-a]pyrimidine	pyrazoles; ring assembly		low
(3-methyl-1-phenyl-5-thieno[2,3-c]pyrazolyl)-(3-methyl-1-pyrazolyl)methanone	pyrazoles; ring assembly		low
3-(4-ethoxyphenyl)-1H-pyrazole-5-carbohydrazide	pyrazoles; ring assembly		low
3-chloro-6-phenyl-[1,2,4]triazolo[4,3-b]pyridazine	pyridazines; ring assembly		low
3-[2-(4-fluorophenyl)-5-methyl-7-oxo-1H-pyrazolo[1,5-a]pyrimidin-6-yl]propanoic acid ethyl ester	pyrazoles; ring assembly		low
3-(4-methoxyphenyl)-1H-pyrazole-5-carbohydrazide	pyrazoles; ring assembly		low
3-phenyl-5,6,7,8-tetrahydro-1H-pyrazolo[5,1-b]quinazolin-9-one	pyrazoles; ring assembly		low
7,8-dimethoxy-5-methyl-3-phenylpyrazolo[3,4-c]isoquinoline	pyrazoles; ring assembly		low
7,8-dimethoxy-1,5-dimethyl-3-phenylpyrazolo[3,4-c]isoquinoline	pyrazoles; ring assembly		low
4-[(4-chlorophenyl)thio]-5-methyl-2-phenyl-1H-pyrazol-3-one	pyrazoles; ring assembly		low
5-methyl-1-phenyl-4-pyrazolecarboxylic acid (4-methoxyphenyl) ester	pyrazoles; ring assembly		low
5-(4-methylphenyl)-2-phenyl-3-pyrazolamine	pyrazoles; ring assembly		low
N-(4-fluorophenyl)-1-(3-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
4-methoxy-2-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]phenol	pyrazoles; ring assembly		low
4-(2,4-dimethylphenyl)-2H-phthalazin-1-one	pyridazines; ring assembly		low
5-amino-3-ethyl-1-phenyl-4-pyrazolecarbonitrile	pyrazoles; ring assembly		low
1-(4-methylphenyl)sulfonyl-4-phenyl-3-pyrazolamine	pyrazoles; ring assembly		low
LSM-16463	pyrazoles; ring assembly		low
N-cyclopropyl-3-methyl-1-phenyl-5-thieno[2,3-c]pyrazolecarboxamide	pyrazoles; ring assembly		low
7-amino-2-(4-tert-butylphenyl)-6-pyrazolo[1,5-a]pyrimidinecarboxylic acid ethyl ester	pyrazoles; ring assembly		low
2-(4-ethoxyphenyl)-3,4-dimethyl-7-[2-(1-pyrrolidinyl)ethylthio]pyrazolo[3,4-d]pyridazine	pyrazoles; ring assembly		low
8-[1-(3-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]-1,4-dioxa-8-azaspiro[4.5]decane	pyrazoles; ring assembly		low
3-(4-chlorophenyl)-5-propyl-1H-pyrazolo[1,5-a]pyrimidin-7-one	pyrazoles; ring assembly		low
2,5-dimethyl-3-phenyl-7-pyrazolo[1,5-a]pyrimidinamine	pyrazoles; ring assembly		low
3-methyl-N'-(1-oxo-2-phenoxyethyl)-1-phenyl-5-thieno[2,3-c]pyrazolecarbohydrazide	pyrazoles; ring assembly		low
4-[(3,5-dichloro-2-hydroxyphenyl)methylamino]-1,5-dimethyl-2-phenyl-3-pyrazolone	pyrazoles; ring assembly		low
4-(3-bromophenyl)-2-(4-bromophenyl)-7-methylpyrazolo[3,4-d]pyridazine	pyridazines; ring assembly		low
4-(3-bromophenyl)-7-methyl-2-(4-methylphenyl)pyrazolo[3,4-d]pyridazine	pyridazines; ring assembly		low
1-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-(4-methylphenyl)sulfonylurea	pyrazoles; ring assembly		low
2-(4-hydroxyphenyl)-5-methyl-1H-pyrazol-3-one	pyrazoles; ring assembly		low
N-[[3-(4-fluorophenyl)-1-phenyl-4-pyrazolyl]methyl]-1-phenylmethanamine	pyrazoles; ring assembly		low
4-(5-amino-4-phenyl-1-pyrazolyl)benzoic acid	pyrazoles; ring assembly		low
2-[4-[[4-(4-methoxyphenyl)-1-phthalazinyl]amino]phenyl]acetamide	pyridazines; ring assembly		low
N-(3,4-dimethoxyphenyl)-1-(3-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
LSM-28273	pyrazoles; ring assembly		low
N'-[2-[[1-(4-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]thio]-1-oxoethyl]-2-furancarbohydrazide	pyrazoles; ring assembly		low
2-[(4-chlorophenyl)methyl]-6-phenyl-5-(1-piperidinyl)-3-pyridazinone	pyridazines; ring assembly		low
2-[(3-chlorophenyl)methyl]-6-phenyl-5-(1-piperidinyl)-3-pyridazinone	pyridazines; ring assembly		low
6-phenyl-5-(1-piperidinyl)-2-prop-2-enyl-3-pyridazinone	pyridazines; ring assembly		low
1-methyl-5-[(4-methylphenyl)thio]-3-phenyl-4-pyrazolecarbonitrile	pyrazoles; ring assembly		low
3-phenyl-6-(trifluoromethyl)-1H-pyrazolo[4,3-b]pyridine	pyrazoles; ring assembly		low
4-(2,5-dimethoxyphenyl)-3-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1H-1,2,4-triazole-5-thione	pyrazoles; ring assembly		low
5-tert-butyl-3-(4-chlorophenyl)-N-(2-pyridinylmethyl)-7-pyrazolo[1,5-a]pyrimidinamine	pyrazoles; ring assembly		low
N-[2-methoxy-5-(3-methyl-4-oxo-1-phthalazinyl)phenyl]-2-(4-methylphenoxy)acetamide	pyridazines; ring assembly		low
LSM-20639	pyrazoles; ring assembly		low
6-[[(4-chlorophenyl)thio]methyl]-2-phenyl-1,7-dihydropyrazolo[3,4-b]pyridine-3,4-dione	pyrazoles; ring assembly		low
N-(3,4-dichlorophenyl)-2-[4-(4-methoxyphenyl)-1-oxo-2-phthalazinyl]acetamide	pyridazines; ring assembly		low
4-(2,5-dimethoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-1H-1,2,4-triazole-5-thione	pyrazoles; ring assembly		low
N-[5-methyl-2-(4-methylphenyl)-3-pyrazolyl]-2-[(7-methyl-4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-9-yl)oxy]acetamide	pyrazoles; ring assembly		low
5-tert-butyl-2-methyl-3-phenyl-N-(2-pyridinylmethyl)-7-pyrazolo[1,5-a]pyrimidinamine	pyrazoles; ring assembly		low
1-(4-methoxyphenyl)-N-[2-(4-morpholinyl)ethyl]-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
N-(5-tert-butyl-2-phenyl-3-pyrazolyl)-2-[(6-methyl-1H-benzimidazol-2-yl)thio]acetamide	pyrazoles; ring assembly		low
N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-(2-methylphenoxy)propanamide	pyrazoles; ring assembly		low
N-(1,3-benzodioxol-5-ylmethyl)-2-[(3-methyl-4-oxo-5-thiophen-2-yl-2-thieno[2,3-d]pyrimidinyl)thio]acetamide	ring assembly; thiophenes		low
N-[4-(4-methyl-2-thiazolyl)-2-phenyl-3-pyrazolyl]-3-(trifluoromethyl)benzamide	pyrazoles; ring assembly		low
1-(4-fluorophenyl)-3-methyl-5-thieno[2,3-c]pyrazolecarboxylic acid [2-(methylamino)-2-oxoethyl] ester	pyrazoles; ring assembly		low
2-chloro-N-[3-(4-methylphenyl)-1-phenyl-4-pyrazolyl]acetamide	pyrazoles; ring assembly		low
3-(4-methoxyphenyl)-1-phenyl-4-pyrazolamine	pyrazoles; ring assembly		low
N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2,5-diphenyl-3-pyrazolecarboxamide	pyrazoles; ring assembly		low
2-chloro-N-(2-phenyl-5-propyl-3-pyrazolyl)acetamide	pyrazoles; ring assembly		low
2-[[1-oxo-2-(1H-1,2,4-triazol-5-ylthio)ethyl]amino]-4-thiophen-2-yl-3-thiophenecarboxylic acid ethyl ester	ring assembly; thiophenes		low
N-(5-methyl-2-phenyl-3-pyrazolyl)-2-phenoxyacetamide	pyrazoles; ring assembly		low
1-phenyl-N-(3-pyridinylmethyl)-3-thiophen-2-yl-4-pyrazolecarboxamide	pyrazoles; ring assembly		low
N-[[2-(diethylamino)ethylamino]-sulfanylidenemethyl]-3-(4-methoxyphenyl)-1-phenyl-4-pyrazolecarboxamide	pyrazoles; ring assembly		low
3-(4-methoxyphenyl)-N-[[[oxo(pyridin-4-yl)methyl]hydrazo]-sulfanylidenemethyl]-1-phenyl-4-pyrazolecarboxamide	pyrazoles; ring assembly		low
3-methyl-N,1-diphenyl-4-pyrazolecarbothioamide	pyrazoles; ring assembly		low
1-(2-chlorophenyl)-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-3-methyl-5-thieno[2,3-c]pyrazolecarboxamide	pyrazoles; ring assembly		low
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3,5-dimethyl-1-pyrazolyl)benzamide	pyrazoles; ring assembly		low
3-[2-[(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)amino]-2-oxoethyl]-4-oxo-1-phthalazinecarboxylic acid	pyrazoles; ring assembly		low
5-(4-propylphenyl)-1H-pyrazol-3-amine	pyrazoles; ring assembly		low
N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-2-[(6-methyl-1H-benzimidazol-2-yl)thio]acetamide	pyrazoles; ring assembly		low
3-methyl-1-phenyl-5-thieno[2,3-c]pyrazolecarboxylic acid [2-(butylamino)-2-oxoethyl] ester	pyrazoles; ring assembly		low
N2-[5-(4-chlorophenyl)-2-phenyl-3-pyrazolyl]benzene-1,2-diamine	pyrazoles; ring assembly		low
N2-[2-(4-methylphenyl)-5-phenyl-3-pyrazolyl]benzene-1,2-diamine	pyrazoles; ring assembly		low
N2-(5-phenyl-1H-pyrazol-3-yl)benzene-1,2-diamine	pyrazoles; ring assembly		low
2-phenyl-5-thiophen-2-yl-3-pyrazolecarboxylic acid [2-(3-nitroanilino)-2-oxoethyl] ester	pyrazoles; ring assembly		low
2-phenyl-5-thiophen-2-yl-3-pyrazolecarboxylic acid [2-(2-chloro-5-nitroanilino)-2-oxoethyl] ester	pyrazoles; ring assembly		low
2-phenyl-5-thiophen-2-yl-3-pyrazolecarboxylic acid [2-(4-chloro-3-nitroanilino)-2-oxoethyl] ester	pyrazoles; ring assembly		low
N-[[(4-oxo-1-phenyl-5-pyrazolo[3,4-d]pyrimidinyl)amino]-sulfanylidenemethyl]benzamide	pyrazoles; ring assembly		low
N2-[5-(3-chlorophenyl)-2-phenyl-3-pyrazolyl]benzene-1,2-diamine	pyrazoles; ring assembly		low
2-phenyl-5-sulfanylidene-3,7,8,9,10,11-hexahydropyrazolo[4,5]pyrimido[3,5-a]azepin-1-one	pyrazoles; ring assembly		low
3-(3,4-dimethylphenyl)-1-(phenylmethyl)-4-pyrazolecarboxaldehyde	pyrazoles; ring assembly		low
4-(3-methyl-1-phenyl-1H-pyrazolo[3,4-b]quinolin-4-yl)morpholine	pyrazoles; ring assembly		low
N,N-diethyl-5-thiophen-2-yl-2-thiophenecarboxamide	ring assembly; thiophenes		low
2,5-bis(3,5-dimethyl-1-phenyl-4-pyrazolyl)-1,3,4-oxadiazole	pyrazoles; ring assembly		low
4-(3-methylphenyl)-2-(3-nitrophenyl)-3-pyrazolamine	pyrazoles; ring assembly		low
4-(4-methylphenyl)-2-(3-nitrophenyl)-3-pyrazolamine	pyrazoles; ring assembly		low
3-(2,4-dichlorophenyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole	pyrazoles; ring assembly		low
2-(3,5-dimethyl-1-pyrazolyl)benzonitrile	pyrazoles; ring assembly		low
sc 514	ring assembly; thiophenes		low
1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea	pyrazoles; ring assembly		low
3,3-dimethyl-5-oxo-5-[(3-phenyl-1H-pyrazol-5-yl)amino]pentanoic acid	pyrazoles; ring assembly		low
1-[(4-chlorophenyl)-oxomethyl]-5-hydroxy-5-phenyl-4H-pyrazole-3-carboxylic acid methyl ester	pyrazoles; ring assembly		low
6-amino-4-(2-methylpropyl)-3-phenyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; ring assembly		low
1,3,8-trimethyl-5,10-diphenylpyrimido[1,2]pyrrolo[4,5-b]pyridazine-2,4-dione	pyridazines; ring assembly		low
4-(5-methyl-3-oxo-1H-pyrazol-2-yl)benzoic acid	pyrazoles; ring assembly		low
4-[1-(4-chlorophenyl)-4-pyrazolo[3,4-d]pyrimidinyl]-2,6-dimethylmorpholine	pyrazoles; ring assembly		low
1-(4-methoxyphenyl)-N,N-dipropyl-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
2-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-hydroxy-3-phenyl-1-isoindolone	pyrazoles; ring assembly		low
2-(1,3-diphenyl-4-pyrazolyl)-3-(2-furanylmethyl)-4-thiazolidinone	pyrazoles; ring assembly		low
3-(4-fluorophenyl)-N-[3-(1-imidazolyl)propyl]-1-phenyl-4-pyrazolecarboxamide	pyrazoles; ring assembly		low
1-(4-fluorophenyl)-3-methyl-5-thieno[2,3-c]pyrazolecarboxylic acid (2-oxo-3-oxolanyl) ester	pyrazoles; ring assembly		low
3,5-dimethyl-1-phenyl-4-pyrazolecarboxylic acid [2-[4-amino-1-methyl-3-(2-methylpropyl)-2,6-dioxo-5-pyrimidinyl]-2-oxoethyl] ester	pyrazoles; ring assembly		low
4-methyl-3-phenyl-1H-pyrazole-5-carbohydrazide	pyrazoles; ring assembly		low
3-(4-fluorophenyl)-5-(2-furanyl)-2-phenyl-3,4-dihydropyrazole	pyrazoles; ring assembly		low
6-amino-4-(3-furanyl)-3-(4-methoxyphenyl)-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; ring assembly		low
7-(2-ethyl-1-piperidinyl)-5-methyl-2-(3-methylphenyl)pyrazolo[1,5-a]pyrimidine	pyrazoles; ring assembly		low
N-(2,4-dimethoxyphenyl)-2-[1-(3,4-dimethylphenyl)-4-oxo-5-pyrazolo[3,4-d]pyrimidinyl]acetamide	pyrazoles; ring assembly		low
3-[3-(4-methylphenyl)-6-oxo-1-pyridazinyl]-N-[2-(2-methyl-1-piperidinyl)ethyl]propanamide	pyridazines; ring assembly		low
N-[2-(2,4-dimethylphenyl)-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]-1,3-benzodioxole-5-carboxamide	pyrazoles; ring assembly		low
4-morpholinecarboxylic acid [4-[6-amino-5-cyano-3-(4-methylphenyl)-2,4-dihydropyrano[2,3-c]pyrazol-4-yl]phenyl] ester	pyranopyrazole; ring assembly		low
N-(3-chlorophenyl)-2-[1-(3,4-dimethylphenyl)-4-oxo-5-pyrazolo[3,4-d]pyrimidinyl]acetamide	pyrazoles; ring assembly		low
1-(4-chlorophenyl)-5-[1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinyl]-4-pyrazolecarboxylic acid	pyrazoles; ring assembly		low
N-[2-(2,3-dimethylphenyl)-5,5-dioxo-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]-2-methoxybenzamide	pyrazoles; ring assembly		low
3-(4-bromophenyl)-1H-pyrazole-5-carboxylic acid methyl ester	pyrazoles; ring assembly		low
5-methyl-N-(5-methyl-2-phenyl-3-pyrazolyl)-3-isoxazolecarboxamide	pyrazoles; ring assembly		low
2-(4-ethoxyphenyl)-5-[1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinyl]-6-pyrazolo[1,5-a]pyrimidinecarboxylic acid	pyrazoles; ring assembly		low
3-[5-amino-3-(4-chlorophenyl)-1-pyrazolyl]propanoic acid ethyl ester	pyrazoles; ring assembly		low
N-[2-(dimethylamino)ethyl]-2-[3-(4-methylphenyl)-6-oxo-1-pyridazinyl]acetamide	pyridazines; ring assembly		low
3-methyl-N-[2-(4-morpholinyl)ethyl]-1-phenyl-5-thieno[2,3-c]pyrazolecarboxamide	pyrazoles; ring assembly		low
6-amino-4-methyl-3-(4-methylphenyl)-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; ring assembly		low
1,3-diphenyl-4-pyrazolecarboxylic acid [2-[(3,5-dichloro-2-pyridinyl)amino]-2-oxoethyl] ester	pyrazoles; ring assembly		low
4-[3-(1,3-diphenyl-4-pyrazolyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-4-oxobutanoic acid	pyrazoles; ring assembly		low
gtp 14564	pyrazoles; ring assembly		low
2-amino-7,7-dimethyl-5-oxo-4-[1-phenyl-3-(4-propan-2-ylphenyl)-4-pyrazolyl]-6,8-dihydro-4H-1-benzopyran-3-carbonitrile	pyrazoles; ring assembly		low
5-[3-[3-(4-methoxyphenyl)-1-phenyl-4-pyrazolyl]-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-5-oxopentanoic acid	pyrazoles; ring assembly		low
4-[1-(4-bromophenyl)-2-nitroethyl]-5-methyl-2-phenyl-1H-pyrazol-3-one	pyrazoles; ring assembly		low
3-ethyl-2-sulfanylidene-5-thiophen-2-yl-1H-thieno[2,3-d]pyrimidin-4-one	ring assembly; thiophenes		low
5-chloro-4-[methoxy(phenyl)methyl]-1-methyl-3-phenylpyrazole	pyrazoles; ring assembly		low
6-amino-3-(3-methoxyphenyl)-4-(3-thiophenyl)-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; ring assembly		low
5-methyl-3-phenyl-7-(prop-2-enylthio)pyrazolo[1,5-a]pyrimidine	pyrazoles; ring assembly		low
2-[4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-piperidinyl]-3-nitropyridine	pyrazoles; ring assembly		low
2-[(2,6-dichlorophenyl)methyl]-6-phenyl-5-(1-piperidinyl)-3-pyridazinone	pyridazines; ring assembly		low
2-[[1-(4-chlorophenyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]-1-butanol	pyrazoles; ring assembly		low
4-[(2-hydroxy-3-nitrophenyl)-(5-methyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methyl]-5-methyl-2-phenyl-1H-pyrazol-3-one	pyrazoles; ring assembly		low
N-butan-2-yl-2-[[3-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-4-oxo-2-quinazolinyl]thio]acetamide	pyrazoles; ring assembly		low
7-(1-azepanyl)-3-(2-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidine	pyrazoles; ring assembly		low
5-methyl-4-[(5-methyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-(3-nitrophenyl)methyl]-2-phenyl-1H-pyrazol-3-one	pyrazoles; ring assembly		low
4-(3,5-dimethyl-1-pyrazolyl)benzoic acid [2-(4-chloro-2-nitroanilino)-2-oxoethyl] ester	pyrazoles; ring assembly		low
am 281	pyrazoles; ring assembly		low
LSM-28389	pyrazoles; ring assembly		low
LSM-16826	pyrazoles; ring assembly		low
1-(4-methoxyphenyl)-N-(2-oxolanylmethyl)-4-pyrazolo[3,4-d]pyrimidinamine	pyrazoles; ring assembly		low
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol	alkylbenzene; ring assembly		low
4-[1-(4-fluorophenyl)-2-nitroethyl]-5-methyl-2-phenyl-1H-pyrazol-3-one	pyrazoles; ring assembly		low
6-amino-4-(3,5-dimethyl-1-phenyl-4-pyrazolyl)-3-methyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; ring assembly		low
3-(4-ethoxyphenyl)-N-[(1-methyl-4-piperidinylidene)amino]-1H-pyrazole-5-carboxamide	pyrazoles; ring assembly		low
6-[5-chloro-3-methyl-1-(4-methylphenyl)-4-pyrazolyl]-3,4-dimethyl-2-oxo-1,6-dihydropyrimidine-5-carboxylic acid ethyl ester	pyrazoles; ring assembly		low
N-[3-(1-imidazolyl)propyl]-2-methyl-3-phenyl-5-propyl-7-pyrazolo[1,5-a]pyrimidinamine	pyrazoles; ring assembly		low
5-tert-butyl-3-(4-chlorophenyl)-7-(2-ethyl-1-imidazolyl)pyrazolo[1,5-a]pyrimidine	pyrazoles; ring assembly		low
4-[1-(2,4-dichlorophenyl)-2-nitroethyl]-5-(2-hydroxyphenyl)-1,2-dihydropyrazol-3-one	pyrazoles; ring assembly		low
[5-(4-chlorophenyl)-1-(3,4-dichlorophenyl)-3-pyrazolyl]-(4-morpholinyl)methanone	pyrazoles; ring assembly		low
4-[3-(2-chloro-1-oxoethyl)-2,5-dimethyl-1-pyrrolyl]-1,5-dimethyl-2-phenyl-3-pyrazolone	pyrazoles; ring assembly		low
6-amino-1,3-diphenyl-4-(3,4,5-trimethoxyphenyl)-4H-pyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; ring assembly		low
ginkgetin	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	anti-HSV-1 agent; antineoplastic agent; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; metabolite	low
amentoflavone	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite	low
cupressuflavone	biflavonoid; hydroxyflavone; ring assembly	EC 3.4.21.37 (leukocyte elastase) inhibitor; metabolite; radical scavenger	low
robustaflavone	biflavonoid; hydroxyflavone; ring assembly	anti-HBV agent; antineoplastic agent; antioxidant; metabolite	low
sciadopitysin	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	bone density conservation agent; platelet aggregation inhibitor	low
2-(4-fluoro-3-methylphenyl)sulfonyl-5-(2-methoxyphenyl)-3-pyrazolamine	pyrazoles; ring assembly		low
4-[[[3-(2-fluorophenyl)-1-methyl-5-thieno[2,3-c]pyrazolyl]-oxomethyl]amino]-1-piperidinecarboxylic acid ethyl ester	pyrazoles; ring assembly		low
3-(4-chlorophenyl)-N-cyclopropyl-1-methyl-5-thieno[2,3-c]pyrazolecarboxamide	pyrazoles; ring assembly		low
3-(4-chlorophenyl)-1-methyl-N-[(5-methyl-2-furanyl)methyl]-5-thieno[2,3-c]pyrazolecarboxamide	pyrazoles; ring assembly		low
N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-1-(1H-imidazol-5-ylsulfonyl)-3-piperidinecarboxamide	pyrazoles; ring assembly		low
3-(4-chlorophenyl)-1-methyl-N-[3-(1-pyrrolidinyl)propyl]-5-thieno[2,3-c]pyrazolecarboxamide	pyrazoles; ring assembly		low
4-[3-(4-fluorophenyl)-2-methyl-7-oxo-1H-pyrazolo[1,5-a]pyrimidin-5-yl]-1-piperidinecarboxylic acid ethyl ester	pyrazoles; ring assembly		low
N-(6-acetyl-1,3-benzodioxol-5-yl)-5-methyl-2-phenyl-3-pyrazolecarboxamide	pyrazoles; ring assembly		low
3-(4-chlorophenyl)-N-[2-(diethylamino)ethyl]-1-methyl-5-thieno[2,3-c]pyrazolecarboxamide	pyrazoles; ring assembly		low
vinorelbine	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent	low
HTS 01037	ring assembly; thiophenes		low
4,5-diphenyl-2,3-dihydro-1H-pyrazolo[3,4-c]pyridazin-3-one	pyridazines; ring assembly		low
1-(3,4-dimethylphenyl)-4-(4-methyl-1-piperidinyl)phthalazine	pyridazines; ring assembly		low
2-(4-nitrophenoxy)-1-[4-(4-phenyl-1-phthalazinyl)-1-piperazinyl]ethanone	pyridazines; ring assembly		low
3-amino-5-(4-bromophenyl)-4-pyridazinecarbonitrile	pyridazines; ring assembly		low
acuminatin	1-benzofurans; dimethoxybenzene; neolignan; olefinic compound; ring assembly	fungal metabolite; plant metabolite	low
2-(4-methoxyphenyl)-5-[1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinyl]-6-pyrazolo[1,5-a]pyrimidinecarboxylic acid ethyl ester	pyrazoles; ring assembly		low
N-cyclohexyl-2-[[6-(4-ethoxyphenyl)-3-pyridazinyl]thio]acetamide	pyridazines; ring assembly		low
N-(5-methyl-3-isoxazolyl)-2-[[6-(4-methylphenyl)-3-pyridazinyl]thio]acetamide	pyridazines; ring assembly		low
n-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamide	pyridazines; ring assembly		low
N-[4-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)phenyl]cyclohexanecarboxamide	pyridazines; ring assembly		low
6-(4-ethylphenyl)-3-(methylthio)-[1,2,4]triazolo[4,3-b]pyridazine	pyridazines; ring assembly		low
N-(phenylmethyl)-3-[3,4,6-trimethyl-1-(4-methylphenyl)-5-pyrazolo[3,4-b]pyridinyl]propanamide	pyrazoles; ring assembly		low
2-(2,1,3-benzothiadiazol-4-ylsulfonyl)-5-(4-chlorophenyl)-3-pyrazolamine	pyrazoles; ring assembly		low
o-demethyltramadol	alkylbenzene; ring assembly		low
sr 147778	pyrazoles; ring assembly		low
ethiprole	pyrazoles; ring assembly		low
1-(2,4-dichlorophenyl)-6-methyl-N-(1-piperidinyl)-4H-indeno[1,2-c]pyrazole-3-carboxamide	pyrazoles; ring assembly		low
ws-5995 c	benzenes; naphthalenes; ring assembly		low
cc 401	pyrazoles; ring assembly		low
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol	pyrazoles; ring assembly		low
fr 180204	pyrazoles; ring assembly		low
n-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1h-pyrazole-4-carboxamide	aromatic amide; cyclopropanes; organofluorine compound; pyrazoles; ring assembly		low
trametinib	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	low
2-(2,1,3-benzothiadiazol-4-ylsulfonyl)-5-(4-bromophenyl)-3-pyrazolamine	pyrazoles; ring assembly		low
dactolisib	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	low
pyriprole	pyrazoles; ring assembly		low
3-[2-(4-chlorophenyl)-5,7-dimethyl-6-pyrazolo[1,5-a]pyrimidinyl]-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]propanamide	pyrazoles; ring assembly		low
macitentan	aromatic ether; organobromine compound; pyrimidines; ring assembly; sulfamides	antihypertensive agent; endothelin receptor antagonist; orphan drug	low
3-[2-(3,5-dimethoxyphenyl)-5,7-dimethyl-6-pyrazolo[1,5-a]pyrimidinyl]-N-(phenylmethyl)propanamide	pyrazoles; ring assembly		low
[3-(4-bromophenyl)-1H-pyrazol-5-yl]-[4-(3,4-dimethoxyphenyl)sulfonyl-1-piperazinyl]methanone	pyrazoles; ring assembly		low
3-[3-(4-fluorophenyl)-2,5,7-trimethyl-6-pyrazolo[1,5-a]pyrimidinyl]-N-(2-methoxyphenyl)propanamide	pyrazoles; ring assembly		low
N-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)-4-pyrazolyl]methyl]-2-(2-pyridinyl)ethanamine	pyrazoles; ring assembly		low
(3aS,5S,9aS)-5-[1-(2-methoxyphenyl)-4-pyrazolyl]-2-phenyl-3a,4,5,7,8,9-hexahydro-3H-pyrrolo[3,4-h]pyrrolizin-1-one	pyrazoles; ring assembly		low
1-[[3-(3-fluorophenyl)-1-(4-methoxyphenyl)-4-pyrazolyl]methyl]-4-methoxypiperidine	pyrazoles; ring assembly		low
N-[[5-(2,4-difluorophenyl)-1H-pyrazol-4-yl]methyl]-1-(3-thiophenyl)-2-propanamine	pyrazoles; ring assembly		low
N-[[3-(3-methylphenyl)-1-(4-methylphenyl)-4-pyrazolyl]methyl]-3-(1-pyrazolyl)-1-propanamine	pyrazoles; ring assembly		low
1-(1,5-dimethyl-3-pyrazolyl)-N-[[5-(2-fluoro-4-methoxyphenyl)-1H-pyrazol-4-yl]methyl]methanamine	pyrazoles; ring assembly		low
(1R,5S)-6-[[5-(2-fluoro-4-methoxyphenyl)-1H-pyrazol-4-yl]methyl]-6-azabicyclo[3.2.1]octane	pyrazoles; ring assembly		low
1-[[3-(4-fluorophenyl)-1-(4-methylphenyl)-4-pyrazolyl]methyl]-4-[(1-methyl-2-imidazolyl)methyl]piperazine	pyrazoles; ring assembly		low
(3aS,5S,9aS)-2-[(2-methylphenyl)methyl]-5-(1-methyl-3-phenyl-4-pyrazolyl)-3a,4,5,7,8,9-hexahydro-3H-pyrrolo[3,4-h]pyrrolizin-1-one	pyrazoles; ring assembly		low
2-(3,5-dimethyl-1-pyrazolyl)-N-[[3-(4-fluorophenyl)-1-(4-methylphenyl)-4-pyrazolyl]methyl]ethanamine	pyrazoles; ring assembly		low
1-[[3-(2-fluorophenyl)-1-methyl-4-pyrazolyl]methyl]-3-propoxypiperidine	pyrazoles; ring assembly		low
N'-[1-(3,4-dimethylphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]acetohydrazide	pyrazoles; ring assembly		low
5-(4-chlorophenyl)-2-(4-methoxyphenyl)sulfonyl-3-pyrazolamine	pyrazoles; ring assembly		low
1-hydroxy-2-(5-phenyl-1H-pyrazol-3-yl)-4H-1,2,4-benzotriazin-3-one	pyrazoles; ring assembly		low
2-[[6-(4-ethylphenyl)-3-pyridazinyl]thio]-N-(2-oxolanylmethyl)acetamide	pyridazines; ring assembly		low
2-[[1-(4-fluorophenyl)-4-pyrazolo[3,4-d]pyrimidinyl]thio]-N-(2-oxolanylmethyl)acetamide	pyrazoles; ring assembly		low
N-[3-[6-(1-azepanyl)-3-pyridazinyl]phenyl]-4-methylbenzenesulfonamide	pyridazines; ring assembly		low
N-[1-(3-fluorophenyl)-6,6-dimethyl-5,7-dihydro-4H-indazol-4-yl]-2-(2-pyridinylthio)acetamide	pyrazoles; ring assembly		low
N-[1-(2,3-dimethylphenyl)-4,5,6,7-tetrahydroindazol-4-yl]-2,5-dimethyl-3-pyrazolecarboxamide	pyrazoles; ring assembly		low
N-[1-(4-tert-butylphenyl)-4,5,6,7-tetrahydroindazol-4-yl]-4-methyl-5-thiadiazolecarboxamide	pyrazoles; ring assembly		low
dafadine O	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; pyridines; ring assembly	P450 inhibitor	low
N-[1-(3,4-dimethylphenyl)-4,5,6,7-tetrahydroindazol-4-yl]-2,5-dimethyl-3-pyrazolecarboxamide	pyrazoles; ring assembly		low
N-[1-(3,4-dimethylphenyl)-4,5,6,7-tetrahydroindazol-4-yl]-5-(methoxymethyl)-2-furancarboxamide	pyrazoles; ring assembly		low
N-[1-(3,4-dimethylphenyl)-4,5,6,7-tetrahydroindazol-4-yl]-2-(3,5-dimethyl-1-pyrazolyl)acetamide	pyrazoles; ring assembly		low
cep 26401	pyridazines; ring assembly		low
gsk 1070916	pyrazoles; ring assembly		low
difenacoum	benzenes; naphthalenes; ring assembly		low
bromfenacoum	benzenes; naphthalenes; ring assembly		low
flocoumafen	benzenes; naphthalenes; ring assembly		low
gs-5816	carbamate ester; ether; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heteropentacyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor	low
mk-8742	carbamate ester; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heterotetracyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor; hepatoprotective agent	low
N-[3-[(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)amino]-1-isoindolylidene]-2-thiophenecarboxamide	pyrazoles; ring assembly		low
3-(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazol-5-ol	ring assembly; triazoles		low
3-amino-2-phenyl-2H-pyrazolo[4,3-c]pyridine-4,6-diol	pyrazoles; ring assembly		low
4-methyl-3-phenyl-1,2-dihydropyrazolo[3,4-b]pyridin-6-one	pyrazoles; ring assembly		low
scytonemin	enone; organic heterotricyclic compound; organonitrogen heterocyclic compound; polyphenol; ring assembly	bacterial metabolite; biological pigment; ultraviolet filter	low
5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazole	pyrazoles; ring assembly		low
sta 9090	ring assembly; triazoles		low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's	post-2020
aminolevulinic acid	1	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	1
coumarin	1	coumarins	fluorescent dye; human metabolite; plant metabolite	2023	2023	1.0	low	0	0	1
salicylic acid	1	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite	2023	2023	1.0	low	0	0	1
thioctic acid	1	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector	2023	2023	1.0	low	0	0	1
picolinic acid	1	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material	2023	2023	1.0	low	0	0	1
thiamine	1	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	1
3-aminobenzamide	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
pleconaril	1			2023	2023	1.0	low	0	0	1
4-(2-aminoethyl)benzenesulfonylfluoride	1			2023	2023	1.0	low	0	0	1
phenytoin	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent	2023	2023	1.0	low	0	0	1
acetazolamide	1	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor	2023	2023	1.0	low	0	0	1
alprenolol	1	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	2023	2023	1.0	low	0	0	1
amantadine	1	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic	2023	2023	1.0	low	0	0	1
2-aminothiazole	1	1,3-thiazoles; primary amino compound		2023	2023	1.0	low	0	0	1
amodiaquine	1	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug	2023	2023	1.0	low	0	0	1
aspirin	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent	2023	2023	1.0	low	0	0	1
baclofen	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant	2023	2023	1.0	low	0	0	1
benzamide	1	benzamides		2023	2023	1.0	low	0	0	1
camostat	1	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor	2023	2023	1.0	low	0	0	1
camphor, (+-)-isomer	1	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite	2023	2023	1.0	low	0	0	1
candesartan	1	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
cetylpyridinium	1	pyridinium ion		2023	2023	1.0	low	0	0	1
chloroxylenol	1	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide	2023	2023	1.0	low	0	0	1
chlorpromazine	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug	2023	2023	1.0	low	0	0	1
ciprofibrate	1	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug	2023	2023	1.0	low	0	0	1
clomipramine	1	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor	2023	2023	1.0	low	0	0	1
danthron	1	dihydroxyanthraquinone	apoptosis inducer; plant metabolite	2023	2023	1.0	low	0	0	1
deferiprone	1	4-pyridones	iron chelator; protective agent	2023	2023	1.0	low	0	0	1
dipyridamole	1	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent	2023	2023	1.0	low	0	0	1
disulfiram	1	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor	2023	2023	1.0	low	0	0	1
valproic acid	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent	2023	2023	1.0	low	0	0	1
doxazosin	1	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent	2023	2023	1.0	low	0	0	1
ebselen	1	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger	2023	2023	1.0	low	0	0	1
etidronate	1	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator	2023	2023	1.0	low	0	0	1
2-hexyloxybenzamide	1	aromatic ether; benzamides	antifungal agent	2023	2023	1.0	low	0	0	1
brl 42810	1	2-aminopurines; acetate ester	antiviral drug; prodrug	2023	2023	1.0	low	0	0	1
fluphenazine	1	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug	2023	2023	1.0	low	0	0	1
fluorouracil	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic	2023	2023	1.0	low	0	0	1
gabexate	1	benzoate ester		2023	2023	1.0	low	0	0	1
glutaral	1	dialdehyde	cross-linking reagent; disinfectant; fixative	2023	2023	1.0	low	0	0	1
fasudil	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	2023	2023	1.0	low	0	0	1
haloperidol	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist	2023	2023	1.0	low	0	0	1
miltefosine	1	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor	2023	2023	1.0	low	0	0	1
hexylresorcinol	1	resorcinols		2023	2023	1.0	low	0	0	1
beta-thujaplicin	1	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite	2023	2023	1.0	low	0	0	1
hycanthone	1	thioxanthenes	mutagen; schistosomicide drug	2023	2023	1.0	low	0	0	1
hydrochlorothiazide	1	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
hydroxyurea	1	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent	2023	2023	1.0	low	0	0	1
ibuprofen	1	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic	2023	2023	1.0	low	0	0	1
indomethacin	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic	2023	2023	1.0	low	0	0	1
avapro	1	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
itraconazole	1	piperazines		2023	2023	1.0	low	0	0	1
kojic acid	1	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent	2023	2023	1.0	low	0	0	1
lapachol	1			2023	2023	1.0	low	0	0	1
loperamide	1	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist	2023	2023	1.0	low	0	0	1
loratadine	1	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist	2023	2023	1.0	low	0	0	1
losartan	1	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist	2023	2023	1.0	low	0	0	1
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide	1	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1
mafenide	1	aromatic amine		2023	2023	1.0	low	0	0	1
methazolamide	1	sulfonamide; thiadiazoles		2023	2023	1.0	low	0	0	1
methocarbamol	1	aromatic ether; carbamate ester; secondary alcohol		2023	2023	1.0	low	0	0	1
mitoxantrone	1	dihydroxyanthraquinone	analgesic; antineoplastic agent	2023	2023	1.0	low	0	0	1
entinostat	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1
ethylmaleimide	1	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor	2023	2023	1.0	low	0	0	1
nabumetone	1	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug	2023	2023	1.0	low	0	0	1
nafamostat	1	benzoic acids; guanidines		2023	2023	1.0	low	0	0	1
nevirapine	1	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
omeprazole	1	aromatic ether; benzimidazoles; pyridines; sulfoxide		2023	2023	1.0	low	0	0	1
osalmide	1	organic molecular entity		2023	2023	1.0	low	0	0	1
oxethazaine	1	amino acid amide		2023	2023	1.0	low	0	0	1
palmidrol	1	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent	2023	2023	1.0	low	0	0	1
papaverine	1	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent	2023	2023	1.0	low	0	0	1
pentoxifylline	1	oxopurine		2023	2023	1.0	low	0	0	1
perhexiline	1	piperidines	cardiovascular drug	2023	2023	1.0	low	0	0	1
phenazopyridine	1	diaminopyridine; monoazo compound	anticoronaviral agent; carcinogenic agent; local anaesthetic; non-narcotic analgesic	2023	2023	1.0	low	0	0	1
4-phenylbutyric acid	1	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug	2023	2023	1.0	low	0	0	1
phenylmethylsulfonyl fluoride	1	acyl fluoride	serine proteinase inhibitor	2023	2023	1.0	low	0	0	1
pimobendan	1	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent	2023	2023	1.0	low	0	0	1
pj-34	1	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent	2023	2023	1.0	low	0	0	1
praziquantel	1	isoquinolines		2023	2023	1.0	low	0	0	1
probenecid	1	benzoic acids; sulfonamide	uricosuric drug	2023	2023	1.0	low	0	0	1
probucol	1	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug	2023	2023	1.0	low	0	0	1
promazine	1	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist	2023	2023	1.0	low	0	0	1
promethazine	1	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative	2023	2023	1.0	low	0	0	1
propranolol	2	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic	2013	2023	6.0	low	0	1	1
rimantadine	1	alkylamine		2023	2023	1.0	low	0	0	1
rolipram	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor	2023	2023	1.0	low	0	0	1
scriptaid	1	isoquinolines		2023	2023	1.0	low	0	0	1
sebacic acid	1	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	human metabolite; plant metabolite	2023	2023	1.0	low	0	0	1
fenofibrate	1	benzochromenone; delta-lactone; naphtho-alpha-pyrone	platelet aggregation inhibitor; Sir2 inhibitor	2023	2023	1.0	low	0	0	1
imatinib	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	2023	2023	1.0	low	0	0	1
suprofen	1	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug	2023	2023	1.0	low	0	0	1
thalidomide	1	phthalimides; piperidones		2023	2023	1.0	low	0	0	1
ticlopidine	1	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor	2023	2023	1.0	low	0	0	1
triamterene	1	pteridines	diuretic; sodium channel blocker	2023	2023	1.0	low	0	0	1
trifluoperazine	1	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug	2023	2023	1.0	low	0	0	1
triflupromazine	1	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic	2023	2023	1.0	low	0	0	1
trigonelline	1	alkaloid; iminium betaine	food component; human urinary metabolite; plant metabolite	2023	2023	1.0	low	0	0	1
trimethobenzamide	1	benzamides; tertiary amino compound	antiemetic	2023	2023	1.0	low	0	0	1
trimethoprim	1	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
tyrphostin a9	1	alkylbenzene	geroprotector	2023	2023	1.0	low	0	0	1
delavirdine	1	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
vesnarinone	1	organic molecular entity		2023	2023	1.0	low	0	0	1
idoxuridine	1	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor	2023	2023	1.0	low	0	0	1
chloramphenicol	1	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
lysine	1	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	1
phenylethyl alcohol	1	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	1
zoxazolamine	1	benzoxazole		2023	2023	1.0	low	0	0	1
cycloheximide	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
ficusin	1	psoralens	plant metabolite	2023	2023	1.0	low	0	0	1
tubercidin	1	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite	2023	2023	1.0	low	0	0	1
trifluridine	1	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor	2023	2023	1.0	low	0	0	1
9,10-anthraquinone	1	anthraquinone		2023	2023	1.0	low	0	0	1
salicylanilide	1	benzanilide fungicide; salicylamides; salicylanilides		2023	2023	1.0	low	0	0	1
gramine	1	aminoalkylindole; indole alkaloid; tertiary amino compound	antibacterial agent; antiviral agent; plant metabolite; serotonergic antagonist	2023	2023	1.0	low	0	0	1
aminacrine	1	aminoacridines; primary amino compound	acid-base indicator; antiinfective agent; antiseptic drug; fluorescent dye; MALDI matrix material; mutagen	2023	2023	1.0	low	0	0	1
methyl gallate	1	gallate ester	anti-inflammatory agent; antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
monobenzone	1	benzyl ether	allergen; dermatologic drug; melanin synthesis inhibitor	2023	2023	1.0	low	0	0	1
ditiocarb	1	dithiocarbamic acids	chelator; copper chelator	2023	2023	1.0	low	0	0	1
catechin	1	catechin	antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
azacitidine	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent	2023	2023	1.0	low	0	0	1
lucanthone	1	thioxanthenes	adjuvant; antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; mutagen; photosensitizing agent; prodrug; schistosomicide drug	2023	2023	1.0	low	0	0	1
cepharanthine	1	bisbenzylisoquinoline alkaloid; isoquinolines		2023	2023	1.0	low	0	0	1
aloe emodin	1	aromatic primary alcohol; dihydroxyanthraquinone	antineoplastic agent; plant metabolite	2023	2023	1.0	low	0	0	1
chrysophanic acid	1	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite	2023	2023	1.0	low	0	0	1
emetine	1	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
osthol	1	botanical anti-fungal agent; coumarins	metabolite	2023	2023	1.0	low	0	0	1
flavanone	1	flavanones		2023	2023	1.0	low	0	0	1
phloretic acid	1	hydroxy monocarboxylic acid	plant metabolite	2023	2023	1.0	low	0	0	1
oleanolic acid	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite	2023	2023	1.0	low	0	0	1
angelicin	1	furanocoumarin		2023	2023	1.0	low	0	0	1
diperodon	1	carbamate ester		2023	2023	1.0	low	0	0	1
megestrol acetate	1	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive	2023	2023	1.0	low	0	0	1
acetylcysteine	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary	2023	2023	1.0	low	0	0	1
hydroxychloroquine sulfate	1			2023	2023	1.0	low	0	0	1
ethambutol	1	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
metformin hydrochloride	1	hydrochloride	environmental contaminant; hypoglycemic agent; xenobiotic	2023	2023	1.0	low	0	0	1
antimycin a	1	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide	2023	2023	1.0	low	0	0	1
5,5'-dimethyl-2,2'-bipyridyl	1	bipyridines		2023	2023	1.0	medium	0	0	1
dichlorobenzyl alcohol	1	benzyl alcohols; dichlorobenzene	antiseptic drug	2023	2023	1.0	low	0	0	1
stavudine	1	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2023	2023	1.0	low	0	0	1
dideoxyadenosine	1	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor	2023	2023	1.0	low	0	0	1
vidarabine	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic	2023	2023	1.0	low	0	0	1
3-deazaadenosine	1			2023	2023	1.0	low	0	0	1
zalcitabine	1	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
ancitabine	1	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug	2023	2023	1.0	low	0	0	1
chloropyramine	1	aminopyridine		2023	2023	1.0	low	0	0	1
levamisole	1	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator	2023	2023	1.0	low	0	0	1
n'-nitrosonornicotine	1	pyridines; pyrrolidines		2023	2023	1.0	low	0	0	1
daunorubicin	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite	2023	2023	1.0	low	0	0	1
zidovudine	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
ribavirin	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2023	2023	1.0	low	0	0	1
pyridoxal phosphate	1	pyridinecarbaldehyde		2023	2023	1.0	medium	0	0	1
nitazoxanide	1	benzamides; carboxylic ester		2023	2023	1.0	low	0	0	1
captopril	1	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	2023	2023	1.0	low	0	0	1
oltipraz	1	1,2-dithiole; pyrazines	angiogenesis modulating agent; antimutagen; antineoplastic agent; antioxidant; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; neurotoxin; protective agent; schistosomicide drug	2023	2023	1.0	low	0	0	1
fiacitabine	1			2023	2023	1.0	low	0	0	1
ranolazine	1	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol		2023	2023	1.0	low	0	0	1
brequinar	1	biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor	2023	2023	1.0	low	0	0	1
imiquimod	1	imidazoquinoline	antineoplastic agent; interferon inducer	2023	2023	1.0	low	0	0	1
adefovir	1	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent	2023	2023	1.0	low	0	0	1
cidofovir anhydrous	1	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent	2023	2023	1.0	low	0	0	1
celgosivir	1			2023	2023	1.0	low	0	0	1
gemcitabine	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic	2023	2023	1.0	low	0	0	1
lamivudine	1	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug	2023	2023	1.0	low	0	0	1
valsartan	1	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
zanamivir	1	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor	2023	2023	1.0	low	0	0	1
adefovir dipivoxil	1	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug	2023	2023	1.0	low	0	0	1
emtricitabine	1	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
octyl gallate	1	gallate ester	food antioxidant; hypoglycemic agent; plant metabolite	2023	2023	1.0	low	0	0	1
efavirenz	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
nelfinavir	1	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
betulinic acid	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite	2023	2023	1.0	low	0	0	1
arctigenin	1	lignan		2023	2023	1.0	low	0	0	1
baicalin	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug	2023	2023	1.0	low	0	0	1
plerixafor	1	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant	2023	2023	1.0	low	0	0	1
amprenavir	1	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
oseltamivir	1	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic	2023	2023	1.0	low	0	0	1
epigallocatechin gallate	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose	1	gallate ester; galloyl beta-D-glucose	anti-inflammatory agent; antineoplastic agent; geroprotector; hepatoprotective agent; plant metabolite; radiation protective agent; radical scavenger	2023	2023	1.0	low	0	0	1
cephalotaxine	1	benzazepine alkaloid fundamental parent; benzazepine alkaloid; cyclic acetal; enol ether; organic heteropentacyclic compound; secondary alcohol; tertiary amino compound		2023	2023	1.0	medium	0	0	1
desipramine hydrochloride	1	hydrochloride	drug allergen	2023	2023	1.0	low	0	0	1
mefloquine hydrochloride	1	hydrochloride		2023	2023	1.0	low	0	0	1
aloxistatin	1	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor	2023	2023	1.0	low	0	0	1
propazole	1	benzimidazoles		2023	2023	1.0	low	0	0	1
prulifloxacin	1	fluoroquinolone antibiotic; quinolone antibiotic		2023	2023	1.0	low	0	0	1
telmisartan	1	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
bergenin	1	trihydroxybenzoic acid	metabolite	2023	2023	1.0	low	0	0	1
zoledronic acid	1	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent	2023	2023	1.0	low	0	0	1
artemisinin	1	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite	2023	2023	1.0	low	0	0	1
brinzolamide	1	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor	2023	2023	1.0	low	0	0	1
dipropylacetamide	1	fatty amide	geroprotector; metabolite; teratogenic agent	2023	2023	1.0	low	0	0	1
oxprenolol hydrochloride	1			2023	2023	1.0	low	0	0	1
opipramol hydrochloride	1			2023	2023	1.0	low	0	0	1
moroxydine	1	biguanides		2023	2023	1.0	low	0	0	1
thioxolone	1	benzoxathiole	antiseborrheic	2023	2023	1.0	low	0	0	1
honokiol	1	biphenyls		2023	2023	1.0	low	0	0	1
nobiletin	1	methoxyflavone	antineoplastic agent; plant metabolite	2023	2023	1.0	low	0	0	1
lycorine	1	indolizidine alkaloid	anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
leupeptin	1	aldehyde; tripeptide	bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor	2023	2023	1.0	low	0	0	1
tetrandrine	1	bisbenzylisoquinoline alkaloid; isoquinolines		2023	2023	1.0	low	0	0	1
calpeptin	1	amino acid amide		2023	2023	1.0	low	0	0	1
fangchinoline	1	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
maslinic acid	1	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
atovaquone	1	hydroxy-1,2-naphthoquinone		2023	2023	1.0	low	0	0	1
loganin	1	beta-D-glucoside; cyclopentapyran; enoate ester; iridoid monoterpenoid; methyl ester; monosaccharide derivative; secondary alcohol	anti-inflammatory agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
moexipril	1	peptide		2023	2023	1.0	low	0	0	1
aucubin	1	organic molecular entity	metabolite	2023	2023	1.0	low	0	0	1
catalpol	1	organic molecular entity	metabolite	2023	2023	1.0	low	0	0	1
lekoptin	1	2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile		2023	2023	1.0	low	0	0	1
tarenflurbil	1	flurbiprofen		2009	2009	15.0	low	1	0	0
cholanic acid	1	5beta-cholanic acids; cholanic acid		2018	2018	6.0	high	0	1	0
n-methyladenosine	1	methyladenosine		2023	2023	1.0	low	0	0	1
sivelestat	1	N-acylglycine; pivalate ester		2023	2023	1.0	low	0	0	1
pyronaridine	1	aminoquinoline		2023	2023	1.0	low	0	0	1
geniposide	1	terpene glycoside		2023	2023	1.0	low	0	0	1
daidzin	1	7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative	plant metabolite	2023	2023	1.0	low	0	0	1
sophocarpine	1			2023	2023	1.0	low	0	0	1
marimastat	1	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor	2023	2023	1.0	low	0	0	1
elacridar	1			2023	2023	1.0	low	0	0	1
celastrol	1	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite	2023	2023	1.0	low	0	0	1
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine	1	leucine derivative		2023	2023	1.0	low	0	0	1
vadimezan	1	monocarboxylic acid; xanthones	antineoplastic agent	2023	2023	1.0	low	0	0	1
e 64	1	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor	2023	2023	1.0	low	0	0	1
umifenovir	1	indolyl carboxylic acid		2023	2023	1.0	low	0	0	1
safinamide	1	amino acid amide		2023	2023	1.0	low	0	0	1
ilomastat	1	hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid	anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent	2023	2023	1.0	low	0	0	1
atazanavir	1	carbohydrazide	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
vx 497	1			2023	2023	1.0	low	0	0	1
bcx 1812	1	3-hydroxy monocarboxylic acid; acetamides; cyclopentanols; guanidines	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor	2023	2023	1.0	low	0	0	1
naproxen	1	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	2023	2023	1.0	low	0	0	1
olmesartan	1	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent	2023	2023	1.0	low	0	0	1
telbivudine	1	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2023	2023	1.0	low	0	0	1
celastrol methyl ester	1	carboxylic ester		2023	2023	1.0	low	0	0	1
resiquimod	1	imidazoquinoline		2023	2023	1.0	low	0	0	1
tanshinone ii a	1	abietane diterpenoid		2023	2023	1.0	low	0	0	1
anacardic acid	1	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
migalastat	1	piperidines		2023	2023	1.0	low	0	0	1
erlotinib	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor	2023	2023	1.0	low	0	0	1
limonin	1	epoxide; furans; hexacyclic triterpenoid; lactone; limonoid; organic heterohexacyclic compound	inhibitor; metabolite; volatile oil component	2023	2023	1.0	low	0	0	1
scutellarin	1	glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antineoplastic agent; proteasome inhibitor	2023	2023	1.0	low	0	0	1
etravirine	1	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
chelidonine	1	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid		2023	2023	1.0	low	0	0	1
4-n-butylresorcinol	1	resorcinols		2023	2023	1.0	low	0	0	1
darunavir	1	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
dapivirine	1			2023	2023	1.0	low	0	0	1
nsc 74859	1	amidobenzoic acid; monohydroxybenzoic acid; tosylate ester	STAT3 inhibitor	2023	2023	1.0	low	0	0	1
berbamine	1	bisbenzylisoquinoline alkaloid; isoquinolines		2023	2023	1.0	low	0	0	1
u-104	1			2023	2023	1.0	low	0	0	1
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one	1	glycoside		2023	2023	1.0	medium	0	0	1
bortezomib	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor	2023	2023	1.0	low	0	0	1
ritonavir	1	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic	2023	2023	1.0	low	0	0	1
tizoxanide	1	salicylamides		2023	2023	1.0	low	0	0	1
arbutin	1	beta-D-glucoside; monosaccharide derivative	Escherichia coli metabolite; plant metabolite	2023	2023	1.0	low	0	0	1
quinidine	1	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker	2023	2023	1.0	low	0	0	1
conessine	1	steroid alkaloid; tertiary amino compound	antibacterial agent; antimalarial; H3-receptor antagonist; plant metabolite	2023	2023	1.0	low	0	0	1
saquinavir	1	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
abacavir	1	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
linezolid	1	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor	2023	2023	1.0	low	0	0	1
cephaelin	1	pyridoisoquinoline		2023	2023	1.0	low	0	0	1
(-)-usnic acid	1	usnic acid	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor	2023	2023	1.0	medium	0	0	1
acetylleucyl-leucyl-norleucinal	1	aldehyde; tripeptide	cysteine protease inhibitor	2023	2023	1.0	low	0	0	1
resveratrol	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger	2023	2023	1.0	low	0	0	1
tacrolimus	1	macrolide lactam	bacterial metabolite; immunosuppressive agent	2023	2023	1.0	low	0	0	1
lycopene	1	acyclic carotene	antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
zithromax	1	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
roflumilast	1	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor	2023	2023	1.0	low	0	0	1
L-cycloserine	1	4-amino-1,2-oxazolidin-3-one	anti-HIV agent; anticonvulsant; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
h 89	1	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide		2023	2023	1.0	low	0	0	1
bevirimat	1	dicarboxylic acid monoester; monocarboxylic acid; pentacyclic triterpenoid	HIV-1 maturation inhibitor; metabolite	2023	2023	1.0	low	0	0	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	1	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor	2023	2023	1.0	low	0	0	1
tenofovir	1	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
posaconazole	1	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug	2023	2023	1.0	low	0	0	1
gw 257406x	1			2023	2023	1.0	low	0	0	1
shikonin	1	hydroxy-1,4-naphthoquinone		2023	2023	1.0	low	0	0	1
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide	1	tropane alkaloid		2023	2023	1.0	medium	0	0	1
cmx 001	1			2023	2023	1.0	low	0	0	1
amd 8664	1			2023	2023	1.0	medium	0	0	1
bay 41-4109	1			2023	2023	1.0	low	0	0	1
bay 57-1293	1			2023	2023	1.0	low	0	0	1
2'-c-methylcytidine	1			2023	2023	1.0	low	0	0	1
isoxanthohumol	1	flavanones		2023	2023	1.0	low	0	0	1
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide	1	aromatic ether		2023	2023	1.0	low	0	0	1
mecarbinate	1			2023	2023	1.0	low	0	0	1
acetyl-aspartyl-glutamyl-valyl-aspartal	1	tetrapeptide	protease inhibitor	2023	2023	1.0	low	0	0	1
octotropine methylbromide	1			2023	2023	1.0	low	0	0	1
mercaptopurine	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent	2023	2023	1.0	low	0	0	1
jrf 12	1			2023	2023	1.0	low	0	0	1
3,4'-dihydroxyflavone	1			2023	2023	1.0	medium	0	0	1
3-(3,4-dimethoxyphenyl)propenoic acid	1	methoxycinnamic acid		2023	2023	1.0	low	0	0	1
isoferulic acid	1	ferulic acids	antioxidant; biomarker; metabolite	2023	2023	1.0	low	0	0	1
cyclouridine	1			2023	2023	1.0	medium	0	0	1
curcumin	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger	2023	2023	1.0	low	0	0	1
zucapsaicin	1	methoxybenzenes; phenols		2023	2023	1.0	low	0	0	1
nbd 556	1			2023	2023	1.0	low	0	0	1
thioguanine anhydrous	1	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent	2023	2023	1.0	low	0	0	1
4,5,6,7-tetrachloroindan-1,3-dione	1			2023	2023	1.0	high	0	0	1
srpin340	1			2023	2023	1.0	low	0	0	1
pr-619	1			2023	2023	1.0	medium	0	0	1
p5091	1			2023	2023	1.0	low	0	0	1
trovirdine	1			2023	2023	1.0	low	0	0	1
fti 277	1			2023	2023	1.0	high	0	0	1
u 0126	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent	2023	2023	1.0	low	0	0	1
vicriviroc	1	(trifluoromethyl)benzenes		2023	2023	1.0	low	0	0	1
telaprevir	1	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic	2023	2023	1.0	low	0	0	1
orlistat	1	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor	2023	2023	1.0	low	0	0	1
dasatinib	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2023	2023	1.0	low	0	0	1
yya-021	1			2023	2023	1.0	medium	0	0	1
sb 415286	1	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	2023	2023	1.0	low	0	0	1
sitagliptin	1	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic	2023	2023	1.0	low	0	0	1
tak-220	1			2023	2023	1.0	medium	0	0	1
jtk-303	1	aromatic ether; monochlorobenzenes; organofluorine compound; quinolinemonocarboxylic acid; quinolone	HIV-1 integrase inhibitor	2023	2023	1.0	low	0	0	1
nbd 557	1			2023	2023	1.0	medium	0	0	1
5'-o-caffeoylquinic acid	1	cinnamate ester; cyclitol carboxylic acid	plant metabolite	2023	2023	1.0	medium	0	0	1
luteolin-7-glucoside	1	beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
cyclosporine	1			2023	2023	1.0	low	0	0	1
harmine	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite	2023	2023	1.0	low	0	0	1
eprosartan	1	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2023	2023	1.0	low	0	0	1
mycophenolate mofetil	1	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug	2023	2023	1.0	low	0	0	1
entacapone	1	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
amentoflavone	1	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite	2023	2023	1.0	low	0	0	1
baicalein	1	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger	2023	2023	1.0	low	0	0	1
genkwanin	1	dihydroxyflavone; monomethoxyflavone	metabolite	2023	2023	1.0	low	0	0	1
hyperoside	1	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
mangostin	1	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite	2023	2023	1.0	low	0	0	1
3-methylquercetin	1	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	anticoagulant; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite	2023	2023	1.0	low	0	0	1
kaempferide	1	7-hydroxyflavonol; monomethoxyflavone; trihydroxyflavone	antihypertensive agent; metabolite	2023	2023	1.0	low	0	0	1
orientin	1	3'-hydroxyflavonoid; C-glycosyl compound; tetrahydroxyflavone	antioxidant; metabolite	2023	2023	1.0	low	0	0	1
scutellarein	1	tetrahydroxyflavone	metabolite	2023	2023	1.0	low	0	0	1
trans-2,3',4,5'-tetrahydroxystilbene	1	stilbenoid		2023	2023	1.0	low	0	0	1
polydatin	1	beta-D-glucoside; monosaccharide derivative; polyphenol; stilbenoid	anti-arrhythmia drug; antioxidant; geroprotector; hepatoprotective agent; metabolite; nephroprotective agent; potassium channel modulator	2023	2023	1.0	low	0	0	1
chicoric acid	1	organooxygen compound	geroprotector; HIV-1 integrase inhibitor	2023	2023	1.0	low	0	0	1
acteoside	1	catechols; cinnamate ester; disaccharide derivative; glycoside; polyphenol	anti-inflammatory agent; antibacterial agent; antileishmanial agent; neuroprotective agent; plant metabolite	2023	2023	1.0	low	0	0	1
dorzolamide	1	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor	2023	2023	1.0	low	0	0	1
topiramate	1	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker	2023	2023	1.0	low	0	0	1
benzyloxycarbonyl-phe-ala-fluormethylketone	1			2023	2023	1.0	high	0	0	1
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester	1	carboxylic ester; difluorobenzene; dipeptide; tert-butyl ester	EC 3.4.23.46 (memapsin 2) inhibitor	2023	2023	1.0	low	0	0	1
casticin	1	dihydroxyflavone; tetramethoxyflavone	apoptosis inducer; plant metabolite	2023	2023	1.0	low	0	0	1
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	1	dihydroxyflavone; monomethoxyflavone	antineoplastic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor	2023	2023	1.0	low	0	0	1
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside	1	beta-D-glucoside; resorcinols; stilbenoid	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; cyclooxygenase 2 inhibitor; platelet aggregation inhibitor	2023	2023	1.0	low	0	0	1
tyrphostin ag 555	1			2023	2023	1.0	low	0	0	1
pd 151746	1			2023	2023	1.0	medium	0	0	1
lisinopril	1	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	2023	2023	1.0	low	0	0	1
verteporfin	1			2023	2023	1.0	low	0	0	1
batimastat	1	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor	2023	2023	1.0	low	0	0	1
indinavir sulfate	1	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor	2023	2023	1.0	low	0	0	1
solanesol	1	nonaprenol; primary alcohol	plant metabolite	2023	2023	1.0	low	0	0	1
pepstatin	1	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor	2023	2023	1.0	low	0	0	1
l 685458	2	carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic	2009	2023	8.0	low	1	0	1
bms 806	1			2023	2023	1.0	low	0	0	1
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	1			2023	2023	1.0	medium	0	0	1
tulobuterol hydrochloride	1	organic molecular entity		2023	2023	1.0	low	0	0	1
salubrinal	1	aminal; organochlorine compound; quinolines; secondary carboxamide; thioureas		2023	2023	1.0	low	0	0	1
germacrone	1	germacrane sesquiterpenoid; olefinic compound	androgen antagonist; anti-inflammatory agent; antifeedant; antifungal agent; antimicrobial agent; antineoplastic agent; antioxidant; antitussive; antiviral agent; apoptosis inducer; autophagy inducer; hepatoprotective agent; insecticide; neuroprotective agent; plant metabolite; volatile oil component	2023	2023	1.0	low	0	0	1
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid	1			2023	2023	1.0	low	0	0	1
lithospermic acid	1			2023	2023	1.0	medium	0	0	1
laq824	1			2023	2023	1.0	low	0	0	1
ekb 569	1	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor	2023	2023	1.0	low	0	0	1
rilpivirine	1	aminopyrimidine; nitrile	EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one	1	germacranolide		2023	2023	1.0	medium	0	0	1
4,5-di-O-caffeoylquinic acid	1	quinic acid		2023	2023	1.0	low	0	0	1
indigo carmine	1			2023	2023	1.0	low	0	0	1
artesunate	1	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer	2023	2023	1.0	low	0	0	1
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	1	oligopeptide		2023	2023	1.0	low	0	0	1
vildagliptin	1	amino acid amide		2023	2023	1.0	low	0	0	1
belinostat	1	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1
hdac-42	1	amidobenzoic acid		2023	2023	1.0	low	0	0	1
chlorhexidine	1	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent	2023	2023	1.0	low	0	0	1
gs-7340	1	6-aminopurines; ether; isopropyl ester; L-alanine derivative; phosphoramidate ester	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug	2023	2023	1.0	low	0	0	1
iniparib	1	carbonyl compound; organohalogen compound		2023	2023	1.0	low	0	0	1
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide	1			2023	2023	1.0	low	0	0	1
pri-2205	1			2023	2023	1.0	low	0	0	1
mk 0752	2			2018	2023	3.5	medium	0	1	1
givinostat	1	carbamate ester		2023	2023	1.0	low	0	0	1
pd 144418	1			2023	2023	1.0	medium	0	0	1
bicyclol	1			2023	2023	1.0	low	0	0	1
midostaurin	1	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2023	2023	1.0	low	0	0	1
ly 450139	4	peptide		2009	2023	8.2	high	1	2	1
mocetinostat	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	2023	2023	1.0	low	0	0	1
rivaroxaban	1	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	2023	2023	1.0	low	0	0	1
sb 3ct compound	1	aromatic ether		2023	2023	1.0	low	0	0	1
ginsenoside rb1	1	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger	2023	2023	1.0	low	0	0	1
rucaparib	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-	1	organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2023	2023	1.0	low	0	0	1
cetilistat	1	benzoxazine		2023	2023	1.0	low	0	0	1
ym 201636	1	aromatic amide		2023	2023	1.0	low	0	0	1
chf 5074	1			2018	2018	6.0	low	0	1	0
linagliptin	1	aminopiperidine; quinazolines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent	2023	2023	1.0	low	0	0	1
azd 6244	1	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2023	2023	1.0	low	0	0	1
odanacatib	1			2023	2023	1.0	low	0	0	1
apilimod	1			2023	2023	1.0	low	0	0	1
apixaban	1	aromatic ether; lactam; piperidones; pyrazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	2023	2023	1.0	low	0	0	1
betrixaban	1	benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	2023	2023	1.0	low	0	0	1
edoxaban	1	chloropyridine; monocarboxylic acid amide; tertiary amino compound; thiazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor; platelet aggregation inhibitor	2023	2023	1.0	low	0	0	1
saracatinib	1	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent	2023	2023	1.0	low	0	0	1
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	1	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic	2023	2023	1.0	low	0	0	1
ly 411575	2	dibenzoazepine; difluorobenzene; lactam; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor	2009	2023	8.0	low	1	0	1
galidesivir	1			2023	2023	1.0	low	0	0	1
PB28	1	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist	2023	2023	1.0	low	0	0	1
degrasyn	1			2023	2023	1.0	low	0	0	1
epoxomicin	1	morpholines; tripeptide	proteasome inhibitor	2023	2023	1.0	low	0	0	1
bms 477118	1	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent	2023	2023	1.0	low	0	0	1
pha 680632	1			2023	2023	1.0	low	0	0	1
4-(2-((1r)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid	1	sulfonamide		2009	2009	15.0	low	1	0	0
tmc 353121	1			2023	2023	1.0	medium	0	0	1
amd 070	1	aminoquinoline		2023	2023	1.0	low	0	0	1
begacestat	3			2009	2013	12.3	high	1	2	0
danoprevir	1			2023	2023	1.0	low	0	0	1
bms-626529	1			2023	2023	1.0	low	0	0	1
bms-663068	1			2023	2023	1.0	low	0	0	1
amenamevir	1			2023	2023	1.0	low	0	0	1
vx 765	1	dipeptide		2023	2023	1.0	low	0	0	1
Dihydrotanshinone I	1	abietane diterpenoid	anticoronaviral agent	2023	2023	1.0	low	0	0	1
alogliptin	1	nitrile; piperidines; primary amino compound; pyrimidines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent	2023	2023	1.0	low	0	0	1
fr 180204	1	pyrazoles; ring assembly		2023	2023	1.0	low	0	0	1
quisinostat	1	indoles		2023	2023	1.0	low	0	0	1
carfilzomib	1	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor	2023	2023	1.0	low	0	0	1
e 2012	1			2018	2018	6.0	low	0	1	0
hcv 796	1			2023	2023	1.0	low	0	0	1
mrk 560	1			2009	2009	15.0	low	1	0	0
resminostat	1			2023	2023	1.0	low	0	0	1
zk 756326	1	aromatic ether		2023	2023	1.0	medium	0	0	1
balapiravir	1			2023	2023	1.0	low	0	0	1
trametinib	1	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2023	2023	1.0	low	0	0	1
deoxyarbutin	1			2023	2023	1.0	low	0	0	1
abexinostat	1	benzofurans		2023	2023	1.0	low	0	0	1
silvestrol	1	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite	2023	2023	1.0	low	0	0	1
narlaprevir	1	azabicyclohexane; cyclopropanes; pyrrolidinecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide; ureas	anticoronaviral agent; antiviral drug; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; hepatitis C protease inhibitor	2023	2023	1.0	low	0	0	1
teneligliptin	1	amino acid amide		2023	2023	1.0	medium	0	0	1
dextrothyroxine	1			2023	2023	1.0	low	0	0	1
veliparib	1	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
pf 03491390	1			2023	2023	1.0	low	0	0	1
alloin	1	anthracenes; C-glycosyl compound; cyclic ketone; phenols	laxative; metabolite	2023	2023	1.0	high	0	0	1
mdv 3100	1	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent	2023	2023	1.0	low	0	0	1
bms-650032	1	oligopeptide		2023	2023	1.0	low	0	0	1
rg 7128	1			2023	2023	1.0	low	0	0	1
oritavancin	1	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent	2023	2023	1.0	low	0	0	1
pevonedistat	1	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer	2023	2023	1.0	low	0	0	1
uk 453,061	1	aromatic ether		2023	2023	1.0	low	0	0	1
N-(2-aminophenyl)-2-pyrazinecarboxamide	1	aromatic amide		2023	2023	1.0	high	0	0	1
tegobuvir	1			2023	2023	1.0	low	0	0	1
pf-429242	1			2023	2023	1.0	low	0	0	1
olaparib	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
cx 4945	1			2023	2023	1.0	low	0	0	1
pci 34051	1	indolecarboxamide		2023	2023	1.0	low	0	0	1
lomibuvir	1	thiophenecarboxylic acid		2023	2023	1.0	low	0	0	1
delanzomib	1	C-terminal boronic acid peptide; phenylpyridine; secondary alcohol; threonine derivative	antineoplastic agent; apoptosis inducer; proteasome inhibitor	2023	2023	1.0	low	0	0	1
pitavastatin(1-)	1	hydroxy monocarboxylic acid anion		2023	2023	1.0	high	0	0	1
GRL-0617	1	benzamides; naphthalenes; secondary carboxamide; substituted aniline	anticoronaviral agent; protease inhibitor	2023	2023	1.0	low	0	0	1
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester	1	carbamate ester		2023	2023	1.0	low	0	0	1
niraparib	1	2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent	2023	2023	1.0	low	0	0	1
jzl 184	1	benzodioxoles		2023	2023	1.0	low	0	0	1
gsk 650394	1	phenylpyridine		2023	2023	1.0	low	0	0	1
oprozomib	1			2023	2023	1.0	low	0	0	1
az 960	1			2023	2023	1.0	low	0	0	1
golgicide a	1	diastereoisomeric mixture	cis-Golgi ArfGEF GBF inhibitor	2023	2023	1.0	low	0	0	1
cobicistat	1	1,3-thiazoles; carbamate ester; monocarboxylic acid amide; morpholines; ureas	P450 inhibitor	2023	2023	1.0	low	0	0	1
bms-790052	1	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor	2023	2023	1.0	low	0	0	1
ixazomib	1	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor	2023	2023	1.0	low	0	0	1
ucph 101	1			2023	2023	1.0	low	0	0	1
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine	1	aryl sulfide; thienopyrimidine		2023	2023	1.0	low	0	0	1
baricitinib	1	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent	2023	2023	1.0	low	0	0	1
KOM70144	1	acetamides; benzamides; naphthalenes; secondary carboxamide	anticoronaviral agent; protease inhibitor	2023	2023	1.0	high	0	0	1
e-52862	1			2023	2023	1.0	low	0	0	1
ly2811376	1			2023	2023	1.0	low	0	0	1
anagliptin	1	amino acid amide		2023	2023	1.0	low	0	0	1
gardiquimod	1			2023	2023	1.0	low	0	0	1
grazoprevir	1	aromatic ether; azamacrocycle; carbamate ester; cyclopropanes; lactam; N-sulfonylcarboxamide; quinoxaline derivative	antiviral drug; hepatitis C protease inhibitor; hepatoprotective agent	2023	2023	1.0	low	0	0	1
abt-450	1			2023	2023	1.0	low	0	0	1
letermovir	1			2023	2023	1.0	low	0	0	1
sofosbuvir	1	isopropyl ester; L-alanyl ester; nucleotide conjugate; organofluorine compound; phosphoramidate ester	antiviral drug; hepatitis C protease inhibitor; prodrug	2023	2023	1.0	low	0	0	1
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine	1	benzoxazole		2023	2023	1.0	low	0	0	1
blz 945	1			2023	2023	1.0	medium	0	0	1
azd3839	1			2023	2023	1.0	medium	0	0	1
pf 3084014	2			2018	2023	3.5	low	0	1	1
unc 0638	1	quinazolines		2023	2023	1.0	low	0	0	1
gs-9620	1			2023	2023	1.0	low	0	0	1
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide	1			2023	2023	1.0	low	0	0	1
jq1 compound	1	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer	2023	2023	1.0	low	0	0	1
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone	1			2023	2023	1.0	low	0	0	1
gsk525762a	1	benzodiazepine		2023	2023	1.0	low	0	0	1
ML240	1	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent	2023	2023	1.0	low	0	0	1
birinapant	1	dipeptide		2023	2023	1.0	low	0	0	1
ly2886721	1			2023	2023	1.0	medium	0	0	1
nms-p118	1			2023	2023	1.0	medium	0	0	1
tubastatin a	1	hydroxamic acid; pyridoindole; tertiary amino compound	EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1
pracinostat	1	benzimidazole; hydroxamic acid; olefinic compound; tertiary amino compound	antimalarial; antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	1
spautin-1	1			2023	2023	1.0	low	0	0	1
ldn 57444	1			2023	2023	1.0	low	0	0	1
gsk1210151a	1	imidazoquinoline		2023	2023	1.0	low	0	0	1
i-bet726	1			2023	2023	1.0	low	0	0	1
(r)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1h-pyrazolo(4,3-c)quinoline	2			2013	2013	11.0	high	0	2	0
acy-1215	1	pyrimidinecarboxylic acid		2023	2023	1.0	low	0	0	1
cudc-907	1			2023	2023	1.0	low	0	0	1
mobic	1	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug	2023	2023	1.0	low	0	0	1
tipranavir	1	sulfonamide	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	1
tasquinimod	1			2023	2023	1.0	low	0	0	1
gsk1265744	1	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor	2023	2023	1.0	low	0	0	1
abt-267	1	aromatic amide; carbamate ester; dipeptide; pyrrolidines	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor	2023	2023	1.0	low	0	0	1
abt-333	1	aromatic ether; naphthalenes; pyrimidone; sulfonamide	antiviral drug; nonnucleoside hepatitis C virus polymerase inhibitor	2023	2023	1.0	low	0	0	1
rgfp966	1			2023	2023	1.0	low	0	0	1
rg2833	1			2023	2023	1.0	medium	0	0	1
pi-1840	1			2023	2023	1.0	medium	0	0	1
acy-738	1			2023	2023	1.0	medium	0	0	1
pelabresib	1	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor	2023	2023	1.0	low	0	0	1
gs-5806	1			2023	2023	1.0	low	0	0	1
doravirine	1			2023	2023	1.0	low	0	0	1
gn6958	1			2023	2023	1.0	high	0	0	1
vx-787	1			2023	2023	1.0	low	0	0	1
ledipasvir	1	azaspiro compound; benzimidazole; bridged compound; carbamate ester; carboxamide; fluorenes; imidazoles; L-valine derivative; N-acylpyrrolidine; organofluorine compound	antiviral drug; hepatitis C protease inhibitor	2023	2023	1.0	low	0	0	1
gs-5816	1	carbamate ester; ether; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heteropentacyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor	2023	2023	1.0	low	0	0	1
g007-lk	1			2023	2023	1.0	low	0	0	1
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide	1			2023	2023	1.0	low	0	0	1
selinexor	1			2023	2023	1.0	low	0	0	1
verdinexor	1			2023	2023	1.0	low	0	0	1
cb-839	1			2023	2023	1.0	low	0	0	1
mk-8742	1	carbamate ester; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heterotetracyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor; hepatoprotective agent	2023	2023	1.0	low	0	0	1
atglistatin	1			2023	2023	1.0	low	0	0	1
xen445	1			2023	2023	1.0	high	0	0	1
santacruzamate a	1	organonitrogen compound; organooxygen compound		2023	2023	1.0	medium	0	0	1
ldc4297	1	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2023	2023	1.0	medium	0	0	1
enasidenib	1	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	2023	2023	1.0	low	0	0	1
s 8932	1	aromatic amine; C-nucleoside; carboxylic ester; nitrile; phosphoramidate ester; pyrrolotriazine	anticoronaviral agent; antiviral drug; prodrug	2023	2023	1.0	low	0	0	1
entecavir	1	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2023	2023	1.0	low	0	0	1
acyclovir	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug	2023	2023	1.0	low	0	0	1
nu 1025	1	phenols; quinazolines	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
didanosine	1	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor	2023	2023	1.0	low	0	0	1
ganciclovir	1	2-aminopurines; oxopurine	antiinfective agent; antiviral drug	2023	2023	1.0	low	0	0	1
valacyclovir	1	L-valyl ester	antiviral drug	2023	2023	1.0	low	0	0	1
penciclovir	1	2-aminopurines; propane-1,3-diols	antiviral drug	2023	2023	1.0	low	0	0	1
4-hydroxyquinazoline	1	quinazolines		2023	2023	1.0	low	0	0	1
tegaserod	1	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist	2023	2023	1.0	low	0	0	1
norclozapine	1	dibenzodiazepine; organochlorine compound; piperazines	delta-opioid receptor agonist; metabolite; serotonergic antagonist	2023	2023	1.0	low	0	0	1
pemetrexed	1	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor	2023	2023	1.0	low	0	0	1
aprepitant	1	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist	2023	2023	1.0	low	0	0	1
azilsartan	1	1,2,4-oxadiazole; aromatic ether; benzimidazolecarboxylic acid	angiotensin receptor antagonist; antihypertensive agent	2023	2023	1.0	low	0	0	1
hesperadin	1			2023	2023	1.0	low	0	0	1
6-bromoindirubin-3'-acetoxime	1			2023	2023	1.0	high	0	0	1
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide	1	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor	2023	2023	1.0	medium	0	0	1
XL413	1	benzofuropyrimidine; organochlorine compound; pyrrolidines	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	2023	2023	1.0	medium	0	0	1
me0328	1			2023	2023	1.0	medium	0	0	1
nvp-tnks656	1			2023	2023	1.0	medium	0	0	1

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	2000's	2010's	post-2020
carbamates	1	amino-acid anion		2012	2012	12.0	low	0	0	1	0
inositol	1	cyclitol; hexol		2020	2020	4.0	low	0	0	1	0
orotic acid	1	pyrimidinemonocarboxylic acid	Escherichia coli metabolite; metabolite; mouse metabolite	2020	2020	4.0	low	0	0	1	0
succinic acid	1	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent	2015	2015	9.0	low	0	0	1	0
clioquinol	1	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator	2020	2020	4.0	low	0	0	1	0
flurbiprofen	1	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2020	2020	4.0	low	0	0	1	0
sulfamerazine	1	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen	2020	2020	4.0	low	0	0	1	0
alanine	4	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite	2011	2021	7.8	low	0	0	3	1
lactose	1	lactose		2019	2019	5.0	low	0	0	1	0
valine	1	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite	2012	2012	12.0	low	0	0	1	0
acetonitrile	2	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent	2010	2012	13.0	low	0	1	1	0
thiophenes	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent	2013	2013	11.0	low	0	0	1	0
quinazolines	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines		2015	2015	9.0	low	0	0	1	0
tarenflurbil	1	flurbiprofen		2020	2020	4.0	low	0	0	1	0
hydroxypropylmethylcellulose acetate succinate	1			2015	2015	9.0	low	0	0	1	0
gefitinib	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	2015	2015	9.0	low	0	0	1	0
s 1033	1	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2016	2016	8.0	low	0	0	1	0
an-1792	1			2020	2020	4.0	low	0	0	1	0
acitretin	1	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug	2020	2020	4.0	low	0	0	1	0
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester	1	carboxylic ester; difluorobenzene; dipeptide; tert-butyl ester	EC 3.4.23.46 (memapsin 2) inhibitor	2018	2018	6.0	low	0	0	1	0
sulfenamide	1			2020	2020	4.0	low	0	0	1	0
2-phenylbenzothiazole	1			2020	2020	4.0	low	0	0	1	0
oxadiazoles	29			2010	2021	9.4	low	5	1	27	1
begacestat	1			2013	2013	11.0	low	0	0	1	0
hes1 protein, human	1			2012	2012	12.0	low	1	0	1	0
bms-790052	1	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor	2012	2012	12.0	low	0	0	1	0
ly2811376	1			2013	2013	11.0	low	0	0	1	0
methylcellulose	2			2015	2019	7.0	low	0	0	2	0
transforming growth factor beta	1			2015	2015	9.0	low	0	0	1	0
amyloid beta-peptides	2			2012	2012	12.0	low	2	0	2	0

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	2000's	2010's	post-2020
Acute Confusional Senile Dementia	0	12	2009	2023	9.0	high	2	1	10	1
Acute Liver Injury, Drug-Induced	0	1	2015	2015	9.0	low	0	0	1	0
Aging	0	1	2012	2012	12.0	low	1	0	1	0
Alzheimer Disease	1	12	2009	2023	9.0	high	2	1	10	1
Amyloid Deposits	0	1	2018	2018	6.0	low	0	0	1	0
Anxiety	0	1	2020	2020	4.0	low	0	0	1	0
Atrophy	0	1	2015	2015	9.0	low	1	0	1	0
Body Weight	0	1	2012	2012	12.0	low	1	0	1	0
Cancer of Lung	0	1	2015	2015	9.0	low	0	0	1	0
Cancer of Skin	0	1	2015	2015	9.0	low	1	0	1	0
Chemical and Drug Induced Liver Injury	0	1	2015	2015	9.0	low	0	0	1	0
Cirrhosis, Liver	0	1	2015	2015	9.0	low	0	0	1	0
Cognitive Decline	0	1	2015	2015	9.0	low	1	0	1	0
Cognitive Dysfunction	0	1	2015	2015	9.0	low	1	0	1	0
Congenital Zika Syndrome	0	1	2020	2020	4.0	low	0	0	1	0
Depression	0	1	2020	2020	4.0	low	0	0	1	0
Diarrhea	0	1	2020	2020	4.0	low	0	0	1	0
Disease Exacerbation	0	1	2015	2015	9.0	low	1	0	1	0
Disease Models, Animal	0	2	2015	2020	6.5	low	0	0	2	0
Drop Attack	0	1	2020	2020	4.0	low	0	0	1	0
Emesis	0	1	2020	2020	4.0	low	0	0	1	0
Exanthem	0	1	2020	2020	4.0	low	0	0	1	0
Exanthema	0	1	2020	2020	4.0	low	0	0	1	0
Fatigue	0	1	2020	2020	4.0	low	0	0	1	0
Lassitude	0	1	2020	2020	4.0	low	0	0	1	0
Liver Cirrhosis	0	1	2015	2015	9.0	low	0	0	1	0
Lung Neoplasms	0	1	2015	2015	9.0	low	0	0	1	0
Neuroblastoma	0	1	2018	2018	6.0	low	0	0	1	0
Prodromal Characteristics	0	1	2015	2015	9.0	low	1	0	1	0
Sensitivity and Specificity	0	1	2010	2010	14.0	low	0	1	0	0
Skin Neoplasms	0	1	2015	2015	9.0	low	1	0	1	0
Syncope	0	1	2020	2020	4.0	low	0	0	1	0
Vomiting	0	1	2020	2020	4.0	low	0	0	1	0
Zika Virus Infection	0	1	2020	2020	4.0	low	0	0	1	0

Safety/Toxicity (4)

Article	Year
Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat. Toxicological sciences : an official journal of the Society of Toxicology, , 06-01, Volume: 163, Issue:2	2018
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clinical pharmacokinetics, , Oct-01, Volume: 51, Issue:10	2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Archives of neurology, , Volume: 69, Issue:11	2012
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat. British journal of clinical pharmacology, , Volume: 75, Issue:1	2013

Long-term Use (1)

Article	Year
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. The Journal of pharmacology and experimental therapeutics, , Volume: 344, Issue:3	2013

Pharmacokinetics (4)

Article	Year
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clinical pharmacokinetics, , Oct-01, Volume: 51, Issue:10	2012
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat. British journal of clinical pharmacology, , Volume: 75, Issue:1	2013
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clinical therapeutics, , Volume: 34, Issue:3	2012
Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors. The Journal of pharmacology and experimental therapeutics, , Volume: 339, Issue:3	2011

Bioavailability (2)

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019
Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. Analytical chemistry, , Jun-05, Volume: 84, Issue:11	2012

Dosage (6)

Article	Year
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog. Bioorganic & medicinal chemistry letters, , 02-01, Volume: 30, Issue:3	2020
Elucidating spray-dried dispersion dissolution mechanisms with focused beam reflectance measurement: contribution of polymer chemistry and particle properties to performance. Pharmaceutical development and technology, , Volume: 24, Issue:9	2019
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clinical pharmacokinetics, , Oct-01, Volume: 51, Issue:10	2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Archives of neurology, , Volume: 69, Issue:11	2012
Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. Analytical chemistry, , Jun-05, Volume: 84, Issue:11	2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clinical therapeutics, , Volume: 34, Issue:3	2012

bms 708163

Description

Cross-References

Synonyms (65)

Drug Classes (2)

Protein Targets (7)

Potency Measurements

Inhibition Measurements

Other Measurements

Bioassays (101)

Research

Studies (46)

Study Types

Related Drugs (929)

Drugs in this Class (367)

Drugs Involved in Assays Together (542)

Drugs Researched Together (30)

Related Conditions (34)

Safety/Toxicity (4)

Long-term Use (1)

Pharmacokinetics (4)

Bioavailability (2)

Dosage (6)